

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number
WO 01/81295 A1

(51) International Patent Classification⁷: **C07C 215/54**,
217/60, 215/56, 217/16, 271/24, 233/23, 323/25, C07D
213/38, A61K 31/137, 31/4402, 31/4406, 31/4409, 31/27,
31/165, A61P 25/16

David [US/US]; Pfizer PGRD, Ann Arbor Laboratories,
2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(21) International Application Number: PCT/US01/13176

(74) Agents: **FEDERMAN, Evan, J.**; Warner-Lambert Com-
pany, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).

(22) International Filing Date: 24 April 2001 (24.04.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/199,762 26 April 2000 (26.04.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
WARNER-LAMBERT COMPANY [US/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and



Published:

(75) Inventors/Applicants (*for US only*): **DEORAZIO,**
Russell, Joseph [US/US]; 921 East Pine Hill Drive,
Schenectady, NY 13303 (US). **NIKAM, Sham, Shridhar**
[IN/IN]; Pfizer PGRD, Ann Arbor Laboratories, 2800
Plymouth Road, Ann Arbor, MI 48105 (US). **SCOTT,**
Ian, Leslie [GB/GB]; 25 Lea Drive, Delanson, NY 12053
(US). **SHERER, Brian, Alan** [US/US]; 2209 Marina
Drive, Clifton Park, NY 12065 (US). **WISE, Lawrence,**

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS



(57) Abstract: Described are compounds of Formula I and Formula II and their pharmaceutically acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.



WO 01/81295 A1

CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The invention pertains to (phenylcyclohexyl)amine derivatives as sub type
5 selective N-Methyl-D-Aspartate Antagonists (NMDA).

BACKGROUND OF THE INVENTION

Over excitation of NMDA receptor channel complexes on postsynaptic
neurons following excessive release of glutamic acid from synaptosomes and
glutamic acid from synaptosomes and glial cells results in excessive calcium ion
10 influx into the neuronal cells, which leads to their death. This is believed to occur
under ischemic or hypoxic conditions such as stroke, hypoglycemic, cardiac arrest
and physical trauma. An NMDA receptor antagonist might be therapeutically useful
because it may minimize damage of the central nervous system induced by ischemic
or hypoxic conditions. The NMDA receptor channel complex consists of at least
15 three binding domains including a glutamic acid (or NMDA) recognition site, a
channel blocking binding site, and a strychnine-insensitive glycine binding type.
Physiologically, a blockade of at least one of these sites terminates the channel
opening of the NMDA receptor to prevent a calcium ion influx (Nagata R. et al.,
J. Med. Chem., 1994;37:3956-3968.

20 Excessive excitation of NMDA receptor channel complexes by
neurotransmitters may be responsible for the loss of neurons in cerebral vascular
disorders such as cerebral ischemia or cerebral infarction resulting in a range of
conditions such as thromboembolic or hemorrhagic stroke, cerebral vasospasm,
hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, such
25 as from near drowning, pulmonary surgery and cerebral trauma, as well as
lathyrism, Alzheimer's disease, and Huntington's disease. Such conditions
likewise suggest the use of agents that may act as antagonists in the receptors
identified above may lead to treatment of amyotrophic lateral sclerosis (ALS),

schizophrenia, parkinsonism, epilepsy, anxiety, pain, and drug addiction (PCT/EPO 94/01492 having publication number WO#94/26747, Watjen et al., published November 24, 1994).

L-glutamic acid, L-aspartic acid and a number of other closely related amino acids have the ability to activate neurons in the nervous system and therefor the vast majority of excitatory neurons in the mammalian CNS. Interaction with glutamic acid mediated neurotransmission is considered a useful approach in the treatment of neurological and psychiatric diseases (Jacobsen et al., WO#94/26746, published November 24, 1994).

Excitatory amino acid receptor antagonists that block NMDA receptors are recognized for usefulness in the treatment of a variety of disorders. NMDA receptors are intimately involved in the phenomenon of excitotoxicity, which may be a critical determinant of outcome of several neurological disorders. Disorders known to be responsive to blockade of the NMDA receptor include acute cerebral ischemia (stroke or cerebral trauma, for example), muscular spasm, convulsive disorders, neuropathic pain and anxiety, and may be a significant causal factor in chronic neurodegenerative disorders such as Parkinson's disease (Klockgether T., Turski L., *Ann Neurol.* 1993;34:585-593), human immunodeficiency virus (HIV) related neuronal injury, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (Francis P.T., Sims N.R., Procter A.W., Bowen D.M., *J. Neurochem.*, 1993;60(5):1589-1604) and Huntington's disease [see Lipton S., *TINS*, 1993;16:(12):527-532; Lipton S., Rosenberg P.A., *New Eng. J. Med.* 1994;330(9): 613-622 and Bigge C.F., *Biochem. Pharmacol.* 1993;45:1547-1561 and references cited therein]. NMDA receptor antagonists may also be used to prevent tolerance to opiate analgesia or to help control withdrawal symptoms from addictive drugs (Eur P., *Application* 488:959A).


Many of the properties of native NMDA receptors are seen in recombinant homomeric NR1 receptors. These properties are altered by the NR2 subunits. Recombinant NMDA receptors expressed in *Xenopus* Oocytes have been studied by voltage-clamp recording, and have been found to exhibit developmental and regional expression of the mRNAs encoding NMDA receptor subunits. Electrophysiological assays were utilized to characterize the actions of compounds at NMDA receptors expressed in *Xenopus* Oocytes. The compounds

were assayed at four subunit combinations at cloned rat NMDA receptors, corresponding to three putative NMDA receptor subtypes (Moriyoshi et al., *Nature*, 1991;354:31-37; Monyer et al., *Science*, 1992;256:1217-1221; Kutsuwada et al., *Nature*, 1992;358:36-41; Sugihara et al., *Biochem. Biophys. Res. Commun.*, 1992;185:826-832).

Expression cloning of the first NMDA receptor subunit, NMDAR1 (NR1) in Nakanishi's lab in 1991 provided an initial view of the molecular structure of the NMDA receptor (Moriyoshi, supra., 1991). There are several other structurally related subunits (NMDAR2A through NMDAR2D) that join NR1 in heteromeric assemblies to form the functional ion channel complex of the receptor (*Ann Rev. Neurosci.*, 1994;17:31-108). The molecular heterogeneity of NMDA receptors implies a future potential for agents with subtype selective pharmacology.

SUMMARY OF THE INVENTION

Compounds of Formula I



I


or a pharmaceutically acceptable salt thereof

wherein:

Ar is aryl or heteroaryl, which heteroaryl is from 5 to 14 atoms having from 1 to 2 heteroatoms selected from the group consisting of N, O, and S;

Z is $-(C)_{n-}$, $-(C)_q-V-$, $-(C)_q-W-(C)_{n-}$, $-(C)_q-W-(C)_n-V-$, or

R_1	R_1	R_1	R_1	R_1	R_1
R_2	R_2	R_2	R_2	R_2	R_2



wherein V is $-(CH_2)_n-$, $-\overset{\overset{O}{||}}{C}-$, $-S(O)-$, or $-S(O)_2-$,

W is $-(CH_2)_n-$, $-\overset{\overset{O}{||}}{C}-$, $-S(O)-$, $-S(O)_2-$, $-O-$, $-S-$, $-C\equiv C-$, or *entgegen* or *zusammen* $-CH(R_1)=CH(R_2)-$,

d is an integer of from 1 to 2,

n is an integer from 1 to 6,

q is an integer from 0 to 6,

R_1 and R_2 are independently selected from the group consisting of hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, aralkyl, or $N(R_4)(R_5)$ wherein

R_4 and R_5 are independently selected from hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, aminoalkyl, hydroxyalkyl, and thioalkyl;


R is hydrogen, alkyl, $C(O)R_6$, $C(O)OR_6$, $C(O)NHR_6$, aralkyl, hydroxyalkyl, aminoalkyl, amino(hydroxy)alkyl, carboxyalkyl, or OH wherein R_6 is alkyl or aralkyl;

Y is a hydrogen bond donor group;

X is independently selected from hydrogen or an electron withdrawing group; and

* denotes *cis* or *trans* or a mixture thereof.

The invention also relates to compounds of Formula II




II

or a pharmaceutically acceptable salt thereof

wherein:

Ar is aryl or heteroaryl, which heteroaryl is from 5 to 14 atoms having from 1 to 2 heteroatoms selected from N, O, and S;



wherein U is $-\text{CH}_2-$, $-\text{C}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$,

A is $-\text{CH}_2-$, $-\text{C}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$,

d is an integer from 1 to 2,

t is an integer from 1 to 3,

R₁ and R₂ are independently selected from hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, thioalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, guanidiny, (aminocarbonyl)alkyl-, carboxyalkyl-, (methylthio)-alkyl-, or N(R₄)(R₅) wherein R₄ and R₅ are independently selected from hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, ureidoalkyl, aminoalkyl, hydroxyalkyl, or thioalkyl,

R₃ is hydrogen, alkyl, OH, or aralkyl,

R is hydrogen, alkyl, C(O)R₆, C(O)OR₆, C(O)NHR₆, aralkyl, hydroxyalkyl, aminoalkyl, amino(hydroxy)alkyl, carboxyalkyl, or OH wherein R₆ is alkyl or aralkyl;

Y is a hydrogen bond donor group;

X is independently selected from hydrogen or an electron withdrawing group; and

* denotes *cis* or *trans* or a mixture thereof.

The invention is also concerned with a pharmaceutical composition useful for treating disorders responsive to the selective blockade of N-methyl-D-aspartate receptor subtypes utilizing the compounds of Formula I or Formula II and the pharmaceutically acceptable salts thereof, optionally disorders as stroke, cerebral ischemia, trauma, hypoglycemia, neurodegenerative disorders, anxiety, depression, migraine headache, convulsions, aminoglycoside antibiotics-induced

hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.

The invention is also concerned with a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal suffering thereof which comprises administering in unit dosage form, at least one compound represented by Formula I or Formula II above or its pharmaceutically acceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

In the compounds of the present invention preferred are compounds of Formula I or pharmaceutically acceptable salts thereof wherein Y is a hydrogen bond donor group para to cyclohexyl on the phenyl ring selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl; and X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl.

More preferred are compounds of Formula I or pharmaceutically acceptable salts thereof wherein Ar is unsubstituted or substituted phenyl; Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈, and R₈ is alkyl, aralkyl, or aryl; X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

Still more preferred are compounds of Formula I or pharmaceutically acceptable salts thereof wherein Ar is unsubstituted or substituted phenyl; Z is as

defined above and further a group whereby Ar and the nitrogen atom in Formula I are separated by from 2 to 4 atoms; Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈,

5 C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈, and R₈ is alkyl, aralkyl, or aryl;

X is hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, alkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

10 Still more preferred are compounds of Formula I or pharmaceutically acceptable salts thereof where Ar is unsubstituted or substituted phenyl;

Z is -CH₂-(CH₂)_m-, $-(CH_2)_m-\overset{\overset{O}{\parallel}}{C}-$, $-O-(CH_2)_m-$, $-(CH_2)_m-\overset{\overset{CH_3}{|}}{CH}-$,

15 $-(CH_2)_m-\overset{\overset{OH}{|}}{CH}-CH_2-$, $-O-\overset{\overset{CH_3}{|}}{C}-\overset{\overset{O}{\parallel}}{C}-$, $-S-(CH_2)_m-$, $-C\equiv C-CH_2$,
or $-C\equiv C-(CH_2)_2-$

wherein m is an integer 1 to 3;

R is hydrogen, methyl, or C(O)CH₃;

20 Y is a hydrogen bond donor group, which group is OH;

X is hydrogen; and

* denotes *trans*.

Most preferred is a compound selected from those listed below:

25 4-{4-[Ethyl(3-phenylpropyl)amino]cyclohexyl}phenol;
4-{4-[Isopropyl(3-phenylpropyl)amino]cyclohexyl}phenol;
cis-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol;
trans-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol;
cis-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol;
trans-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol;
30 4-(4-Phenethylaminocyclohexyl)phenol;
trans-4-(4-Benzylaminocyclohexyl)phenol;
cis-4-(4-Benzylaminocyclohexyl)phenol;

- trans*-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol;
cis-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol;
trans-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
cis-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
5 *trans*-4-[4-((*R*)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
trans-4-[4-((*S*)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
trans-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol;
cis-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol;
trans-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol;
10 *cis*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol;
4-[4-(5-Phenylpentylamino)cyclohexyl]phenol;
trans-4-[4-((*R*)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]phenol;
cis-4-[4-((*R*)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]phenol;
trans-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol;
15 *cis*-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol;
trans-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol;
cis-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol;
4-[4-((*S*)-1-Methyl-2-phenylethylamino)cyclohexyl]phenol;
trans-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol;
20 *cis*-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol;
trans-4-[4-(3-Pyridin-2-ylpropylamino)cyclohexyl]phenol;
cis-4-[4-(3-Pyridin-2-ylpropylamino)cyclohexyl]phenol;
N-Benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]acetamide;
N-[4-(4-Hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)acetamide;
25 *N*-[4-(4-Hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)carbamic acid
methyl ester;
N-Benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]carbamic acid methyl ester;
4-{4-[Methyl-(3-phenylpropyl)amino]cyclohexyl}phenol;
N-[4-(4-Hydroxyphenyl)cyclohexyl]-3-phenylpropionamide;
30 *N*-[4-(4-Hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxypropionamide;
4-[4-(3-Phenylprop-2-ynylamino)cyclohexyl]phenol;
4-[4-(2-Phenylsulfanylethylamino)cyclohexyl]phenol;
4-{4-[3-(4-Methoxyphenyl)propylamino]cyclohexyl}phenol;

4-{4-[Benzyl(3-phenylpropyl)amino]cyclohexyl}phenol;
4-{4-[methyl(2-phenoxyethyl)amino]cyclohexyl}phenol; and
2-Aminomethyl-4-{4-[ethyl(3-phenylpropyl)amino]cyclohexyl}phenol.

Preferred are compounds of Formula II or pharmaceutically
5 acceptable salts thereof wherein Y is a hydrogen bond donor group para to
cyclohexyl on the phenyl ring selected from the group consisting of OH,
heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH
and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈,
or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl; and X is independently selected
10 from hydrogen or an electron withdrawing group selected from the group
consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl.

More preferred are compounds of Formula II or pharmaceutically
acceptable salts thereof wherein:

Ar is unsubstituted or substituted phenyl;

15 Y is a hydrogen bond donor group selected from the group consisting of OH,
heterocycle, which heterocycle is a carboxylic acid or an amide isostere,
NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈,
C(O)NHR₈, SO₂R₈, or SO₂NHR₈, and R₈ is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group
20 selected from the group consisting of halogen, nitro, cyano, aminoalkyl,
CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

Still more preferred are compounds of Formula II or pharmaceutically
acceptable salts thereof wherein:

25 Ar is unsubstituted or substituted phenyl;

Ar and the nitrogen atom bearing R are separated by 3 or 4 atoms;

Y is a hydrogen bond donor group selected from the group consisting of OH,
heterocycle, which heterocycle is a carboxylic acid or an amide isostere,
NH₂, SH and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈,
30 C(O)NHR₈, SO₂R₈, or SO₂NHR₈, and R₈ is alkyl, aralkyl, or aryl;

10


X is independently selected from hydrogen or an electron withdrawing group
selected from the group consisting of halogen, nitro, cyano, aminoalkyl,
CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

5 Still more preferred are compounds of Formula II or pharmaceutically
acceptable salts thereof wherein:

Ar is unsubstituted or substituted phenyl;

T is



R is hydrogen or methyl;


Y is a hydrogen bond donor group, which group is OH;

25 X is hydrogen; and

* denotes *trans*.

A preferred material is: 4-[4-(2-Phenylaminoethylamino)
cyclohexyl]phenol.


Another preferred compound is that of Formula III



III

with the substituents as described above.

Another preferred compound is that of Formula IV



with the substituents as described above.

5 In compounds of Formulas I-III, *cis* materials are also preferred.

It is to be appreciated that the Y group is a hydrogen bond donor group that is attached at one and only one carbon atom of the phenylene ring.

The term “alkyl” means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified, also known as a
 10 C₁-C₁₂ alkyl, and includes, for example, methyl, ethyl, 1-propyl, and 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl, 1,1-dimethylethyl, 1-pentyl, 2-pentyl, 3-pentyl, 2,2-dimethylpropyl, 1-hexyl, 2-hexyl, 3-hexyl, 4-methyl-1-pentyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 5-methyl-1-hexyl, 1-octyl, 2-octyl, 3-octyl, 4-octyl, 6-methyl-1-heptyl, 5,5-dimethylhexyl, 1-nonyl, 2-nonyl, 1-decyl, 2-decyl,
 15 1-undecyl, 2-undecyl, 1-dodecyl, and 5-dodecyl. Alkyl groups may be unsubstituted or independently substituted by from 1 to 3 substituents selected from F, Cl, Br, I, OH, NH₂, SH, CN, NO₂, OCH₃, OC(O)CH₃, CF₃, OCH₂CH₂OH, NHC(O)CH₃, NHCH₃, or N(CH₃)₂.

Alkyl groups having two or more carbons may optionally contain 1 or
 20 2 sites of unsaturation, the groups being known as alkenyl groups or radicals. Illustrative examples of an alkenyl group or radical having from 2 to 12 carbon atoms, also known as a C₂ to C₁₂ alkenyl, include ethenyl, 1-propenyl, 2-propenyl, 1-buten-1-yl, 2-buten-1-yl, 1-penten-1-yl, 2-penten-1-yl, 1-penten-3-yl, 1-penten-5-yl, 1-hexen-1-yl, 1-hexen-4-yl, 2-hexen-1-yl, 3-hexen-1-yl, 2-octen-3-yl, 5-nonen-2-yl, 4-undecen-4-yl, and 5-dodecen-2-yl.
 25

The term “aryl” means an aromatic carbocyclic ring having from 6 to 10 carbon atoms. Illustrative examples of an aryl group or radical include phenyl,

1-naphthyl, and 2-naphthyl. Aryl groups may be unsubstituted or independently substituted by from 1 to 3 substituents selected from F, Cl, Br, I, OH, NH₂, SH, CN, NO₂, OCH₃, OC(O)CH₃, CF₃, OCH₂CH₂OH, NHC(O)CH₃, NHCH₃, or N(CH₃)₂.

5 The term "aralkyl" means an aryl-alkyl- group or radical wherein aryl and alkyl have the meanings as defined above. Illustrative examples of an arylalkyl group or radical include benzyl, 4-fluorophenylmethyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 3-methyl-3-phenylpropyl, 1-naphthylmethyl, 1-naphthylethyl, 3-(1-naphthyl)-propyl, 4-(1-naphthyl)-butyl, 4-(2-naphthyl)-
10 butyl, 4-phenylheptyl, and 12-(2-hydroxyphenyl)-dodec-3-yl.

 The term "heteroatom" means nitrogen, oxygen, or sulfur.

 The term "heteroaryl" means an unsaturated monocyclic group or radical of 5 or 6 atoms, an unsaturated fused bicyclic group or radical of from 8 to 10 atoms, or an unsaturated fused tricyclic group or radical of from 11 to
15 14 atoms, the cyclic groups having 1 or 2 heteroatoms independently selected from O, N, or S. Illustrative examples of monocyclic heteroaryl include 2- or 3-thienyl, 2- or 3-furanyl, 1-, 2- or 3-pyrrolyl, 1-, 2- or 4-imidazolyl, 1-, 3- or 4-pyrazolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isoxazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridinyl, 3- or 4-pyridazinyl, 2- or 3-pyrazinyl, and 2-,
20 4- or 5-pyrimidinyl. Illustrative examples of bicyclic heteroaryl include 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 2-, 3-, 4-, 5-, 6- or 7-benzo[b]thienyl, 2-, 4-, 5-, 6- or 7-benzofuran, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, and 1-, 2-, 3-, 4-, 5-, 6- or 7-benzimidazolyl. Illustrative examples of tricyclic
25 heteroaryl include 1-, 2-, 3- or 4-dibenzofuranyl, 1-, 2-, 3- or 4-dibenzothieryl and 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-(1,2,3,4-tetrahydroacridinyl). All with the proviso that when Z in Formula I is attached via a heteroatom, Z is attached to a carbon atom of the heteroaryl group or radical. Heteroaryl groups may be unsubstituted or independently substituted by from 1 to 3 substituents selected from F, Cl, Br, I,
30 OH, NH₂, SH, CN, NO₂, OCH₃, OC(O)CH₃, CF₃, OCH₂CH₂OH, NHC(O)CH₃, NHCH₃, or N(CH₃)₂.

As used above, a fused bicyclic group or radical is a group wherein two ring systems share two and only two atoms.

As used above, a fused tricyclic group or radical is a group wherein three ring systems share four and only four atoms.

5 The term "heteroaralkyl" means a heteroaryl-alkyl- group or radical wherein heteroaryl and alkyl have the meanings as defined above. Illustrative examples of an heteroaralkyl group or radical include 4-pyridyl-methyl, (4-fluoroquinolin-2-yl)methyl, 2-(isoxazol-3-yl)ethyl, and 12-(5-chlorothiophen-2-yl)-dodec-3-yl.

10 The term "halogen" means bromine, chlorine, fluorine or iodine.

 The term "aminoalkyl" means an H₂N-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -NH₂.

15 The term "hydroxyalkyl" means an HO-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -OH.

 The term "amino(hydroxy)alkyl" means an H₂N(HO)-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted
20 alkyl group or radical containing from 2 or 3 substituents wherein at least one substituent is OH and one substituent is -NH₂.

 The term "(aminocarbonyl)alkyl" means an H₂NC(O)-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted
25 alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -(O)C-NH₂.

 The term "thioalkyl" means an HS-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -SH.

 The term "(methylthio)-alkyl-" means an CH₃S-alkyl- group or radical
30 wherein alkyl has the meaning as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -SCH₃.

The term "carboxyalkyl" means an HO₂C-alkyl- group or radical wherein alkyl has the meaning as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is -CO₂H.

5 The term "haloalkyl" means a halogen-alkyl- group or radical wherein halogen and alkyl have the meanings as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is selected from F, Cl, Br, or I.

10 The term "ureidoalkyl" means an H₂N-(C=O)-NH-alkyl- group or radical wherein alkyl has the meanings as defined above, which is a substituted alkyl group or radical containing from 1 to 3 substituents wherein at least one substituent is H₂N-(C=O)-NH-.


The term "guanidiny" means an H₂N-(C=NH)-NH- group or radical.

15 The term "hydrogen bond donor groups" means a group or radical selected from OH, heterocycle, which heterocycle is a carboxylic acid or amide isostere NH₂, SH, CH₂-C(O)CH₃, NHR₇ wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, P(O)(O-R₈)₂, SO₂R₈, or SO₂NHR₈ wherein R₈ is alkyl, aralkyl, or aryl. The importance of the hydrogen bond donor group in certain antagonists selective for certain NMDA receptor subunits is known (Chenard
20 B.L., Menniti F.S., *Curr. Pharm. Design* 1999;5:381-404).

 The term "electron withdrawing group" means a group or radical selected from halogen, nitro, cyano, alkyl, CF₃, C(O)CH₃, P(O)(O-R₉)₂, SO₂-R₉, SO₂NHR₉, C(O)NR₉R₉' wherein R₉ is independently selected from C₁-C₆ alkyl or unsubstituted or substituted phenyl, -(C=NH)-NH₂, -(C=NH)-O-alkyl,
25 methoxymethyl, or haloalkyl, wherein the substituents may be F, Cl, Br, I, OH, NH₂, SH, CN, NO₂, OCH₃, OC(O)CH₃, CF₃, OCH₂CH₂OH, NHC(O)CH₃, NHCH₃, or N(CH₃)₂.

 The phrase "heterocycle, which heterocycle is a carboxylic acid or an amide isostere" means a 5- or 6-membered monocyclic ring containing from 1 to
30 4 heteroatoms selected from N, O, and S and providing a hydrogen bond donor

moiety selected from NH, OH, and SH. Illustrative examples include the following structures:



See also Greenwood J.R., Vaccarella G., Cooper H.R., Allan R.D.,
 5 Johnston G.A.R., *Internet Journal of Chemistry*, 1998;1(Article 38) Chart 4).
 Additional examples are well-known to the skilled artisan (see, for example, (i)
 Lipinski C.A., *Annual Reports in Medicinal Chemistry*, 1986;21:Chapter 21,
 Chapter 27; (ii) Thornber C.W., *Chem. Soc. Rev.*, 1979;8:563; (iii) Burger A.,
Progress in Drug Research, 1991;37:288-371).

10 The term "entgegen" means the stereoisomerism about a carbon-carbon
 double bond wherein the highest ranking substituent on each carbon are on
 opposite sides, which substituent ranking is based on the sequence rules of the
 Cahn-Ingold-Prelog system (March J., *Advanced Organic Chemistry*, 4th ed.,
 1992 John Wiley & Sons, New York, pp. 109 and 127 and references cited
 15 therein).


The term "zusammen" means the stereoisomerism about a carbon-carbon double bond wherein the highest ranking substituent on each carbon are on the same side, which substituent ranking is based on the sequence rules of the Cahn-Ingold-Prelog system (March J., *Advanced Organic Chemistry*, 4th ed.,
 5 1992;109,127; John Wiley & Sons, New York, and references cited therein).

The term "cis" means the stereoisomerism about a carbon-carbon double bond, a monocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring wherein the highest ranking substituent on each of the two carbons of relevance are on the same side, which substituent ranking is based on the sequence rules of the Cahn-Ingold-Prelog system (March J., *Advanced Organic Chemistry*, 4th ed.,
 10 1992;109:127-133; John Wiley & Sons, New York, and references cited therein).

The term "trans" means the stereoisomerism about a carbon-carbon double bond, a monocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring wherein the highest ranking substituent on each of the two carbons of relevance are on opposite sides, which substituent ranking is based on the sequence rules of the Cahn-Ingold-Prelog system (March J., *Advanced Organic Chemistry*, 4th ed.,
 15 1992;109,127-133; John Wiley & Sons, New York, and references cited therein).

The terms "cis" or "trans" refers to the relative stereochemistry of the groups attached to the cyclohexyl rings of Formulas I or II at the carbon atoms denoted by "*".
 20

The term "(X)_d" means the group X is present 1 or 2 times on the phenylene to which it is attached, which group is independently selected from hydrogen or an electron withdrawing group wherein the electron withdrawing group is as defined above unless otherwise stated. The groups X can be the same or different.
 25



wherein n is an integer of from 1 to 6 and q is an integer of from 0 to 6 mean a chain of from 1 to 6 carbons or from 0 to 6 carbons, respectively, wherein each carbon is independently substituted, which substituents are the groups
 30

R₁ and R₂, wherein R₁ and R₂ are independently (R₁ and R₂ in each occurrence can be the same or different) selected from the groups consisting of hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, aralkyl, or N(R₄)(R₅) wherein R₄ and R₅ are independently selected from hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, aminoalkyl, hydroxyalkyl and thioalkyl, unless otherwise stated. The groups R₁ can be the same or different, and the groups R₂ can be the same or different.

For purposes of the syntheses of the compounds of the present invention, reactive functional groups present in starting materials, reaction intermediates, or reaction products may be protected during chemical reactions using protecting groups which render the reactive functional groups substantially inert to the reaction conditions (see for example, *Protective Groups in Organic Synthesis*, 2nd ed., Green T.W. and Wuts P.G.: John Wiley & Sons, New York, NY, 1991). Thus, for example, protecting groups such as the following may be utilized to protect suitable amino, hydroxyl, and other groups of related reactivity: carboxylic acyl groups, such as formyl, acetyl, trifluoroacetyl; alkoxycarbonyl groups, such as ethoxycarbonyl, *t*-butoxycarbonyl (BOC), β,β,β -trichloroethoxycarbonyl (TCEC), β -iodoethoxycarbonyl; aryloxycarbonyl groups, such as benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, phenoxycarbonyl; trialkyl silyl groups, such as trimethylsilyl and *t*-butyldimethylsilyl (TBDMS); and groups such as trityl, tetrahydropyranyl, vinyloxycarbonyl, *o*-nitrophenylsulfenyl, diphenylphosphinyl, *p*-toluenesulfonyl, and benzyl may all be utilized. The protecting group may be removed, after completion of the synthetic reaction of interest, by procedures known to those skilled in the art. For example, a BOC group may be removed by acidolysis, a trityl group by hydrogenolysis, TBDMS by treatment with fluoride ions, and TCEC by treatment with Zinc.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R or S configuration. The present invention includes all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all *cis*,

trans, *syn*, *anti*, *entgegen* (E), and *zusammen* (Z) isomers as well as the appropriate mixtures thereof.

Some of the compounds of Formulas I-III are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formulas I-III include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Science*, 1977;66:1-19).

The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are *N,N*-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, *N*-methylglucamine, and procaine (see, for example, Berge, supra., 1977).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

5 The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be
10 administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formulas I-III or a corresponding pharmaceutically acceptable salt of a compound of Formulas I-III.

15 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders,
20 preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape
25 and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax,
30 cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets

and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the

particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as antagonists or as agents for the treatment of diseases, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

Tablet Formulation

Ingredient	Amount (mg)
4-[4-(3-Phenylpropylamino)cyclohexyl]phenol	25
Lactose	50
Cornstarch (for mix)	10
Cornstarch (paste)	10
Magnesium stearate (1%)	5
Total	100

The 4-[4-(3-Phenylpropylamino)cyclohexyl]phenol, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of disease caused by over excitation of NMDA receptor channel complexes.


The compounds of the present invention can be prepared according to the various synthetic schemes that follow. Protecting groups may be used when appropriate throughout many of the schemes. Although specifically noted in certain schemes, the appropriate use and choice of protecting groups is well-known by one skilled in the art, and is not limited to the specific examples below. It is also understood that such groups not only serve to protect chemically reactive sites, but also to enhance solubility or otherwise change physical properties. A good general reference for protecting group preparation and deprotection is "Protective Groups in Organic Synthesis" by Theodora Green, supra., 1991. A number of general reactions such as oxidations and reductions are not shown in detail but can be done by methods understood by one skilled in the art. General transformations are well reviewed in "Comprehensive Organic Transformation" by Richard Larock, and the series "Compendium of Organic Synthetic Methods" (1989) published by Wiley-Interscience. In general, the starting materials were obtained from commercial sources unless otherwise indicated.

Preparation of Compounds

Compounds of Formulas I-III can be prepared by a reductive amination reaction between an amine and 4-(4-hydroxyphenyl)cyclohexanone (Scheme 1). Examples of synthetic procedures for the synthesis of amines and for reductive aminations are included. The amines thus generated can subsequently be converted to amides, carbamates, or more substituted amines. Examples of these processes are included.


23

Scheme 1




Compounds of Formulas I-III can also be prepared from *cis*- or *trans*-1-amino-4-(4-hydroxyphenyl)cyclohexane by alternative approaches including: reductive amination with aldehydes or ketones, amidation, and amidation followed by reduction (Scheme 2), and alkylation (Scheme 3). Examples of these processes are included. A method for the synthesis of *trans*-1-amino-4-(4-hydroxyphenyl)cyclohexane is also included.

Scheme 2



24

Scheme 3



General Methods

HCl salts were prepared by treatment of a MeOH solution of the amine with excess HCl in Et₂O (1 M). The salts were isolated either by filtration if they precipitated directly from the ether solution, or by first removal of the solvent under reduced pressure, and then crystallization (Et₂O/MeOH).

Maleate salts were prepared by treatment of a MeOH solution of the amine with one equivalent of maleic acid in Et₂O. The salts were isolated either by filtration if they precipitated directly from the ether solution, or by first removal of the solvent under reduced pressure, and then crystallization (Et₂O/MeOH).

Purity was determined by reverse phase HPLC by the following methods:

Method A: column: YMC J'Sphere C18, ODS-M80, 150 × 4.6 mm, 4 μ;

solvent A: 0.1% H₃PO₄ in H₂O; solvent B: 0.1% H₃PO₄ in CH₃CN;

gradient: 10-100% B over 15 min; flow: 1 mL·min⁻¹; detection: 210 nm.

Method B: column: YMC J'Sphere C18, ODS-M80, 150 × 4.6 mm, 4 μ;

solvent A: 0.1% H₃PO₄ in H₂O; solvent B: 0.1% H₃PO₄ in MeOH;

gradient: 10-100% B over 15 min; flow: 1 mL·min⁻¹; detection: 210 nm.

Method C: column: Zorbax Eclipse XDB-C8, 150 × 4.6 mm, 4 μ;

solvent A: 1% Et₃N in H₂O, H₃PO₄ (to give a pH of 3);

solvent B: 1% Et₃N in CH₃CN, H₃PO₄ (to give a pH of 3);

gradient: 10-100% B over 15 min; flow: 1 mL·min⁻¹; detection: 210 nm.

Method D: column: Zorbax Eclipse XDB-C8, 150 × 4.6 mm, 4 μ;

solvent A: 1% Et₃N in H₂O, H₃PO₄ (to give a pH of 3);

solvent B: 1% Et₃N in MeOH, H₃PO₄ (to give a pH of 3);

gradient: 10-100% B over 15 min; flow: 1 mL•min⁻¹; detection: 210 nm.

Known Compounds

3-(4-Pyridyl)propylamine (Mayer J.M., Testa B., *Helv. Chim. Acta*, 1982;65:1868-1884)

3-(3-Pyridyl)propylamine (CAS#: 41038-69-1; Mayer Supra., 1982; Hawes, Davis J., *Heterocycl. Chem.*, 1973;10:39)

3-(2-Pyridyl)propylamine (CAS#: 41038-69-1; Mayer, supra., 1982. Other references in Chem. Abs., see search)

4-Phenylbutylamine (Kuelz et al., *Chem. Ber.*, 1939:2161-2165 and commercially available from Aldrich Chemical Company)


5-Phenylpentylamine (Kotschekow and Dudykina, *Zh. Obshch. Khim.*, 1958;28:2399-2403)

2-Methyl-2-phenoxypropionic acid (CAS# 943-45-3; Bischoff, *Chem. Ber.*, 1900;33:933)

Methanesulfonic acid 3-phenyl-prop-2-ynyl ester (CAS# 82490-61-7; Place P., Verniere C., Gore J., *Tetrahedron*, 1981;37:1359-1368)

3-(4-Methoxyphenyl)propionaldehyde (CAS# 20401-88-1; Walker E., *J. Chem. Soc.*, 1947:1571)

Preparation of *trans*-1-Amino-4-(4-hydroxyphenyl)cyclohexane 5



Step 1: To an ice-cold, stirred solution of 4-(4-hydroxyphenyl)-cyclohexanone **1** (5.0 g, 26 mmol) in THF (120 mL), under an N₂ atmosphere, was added L-selectride® (30 mL of a 1.0 M in THF, 30 mmol) dropwise over 15 minutes. The reaction mixture was allowed to warm to room temperature and then stirred overnight. The reaction mixture was diluted with MeOH (100 mL) and concentrated under reduced pressure. The residue was dissolved in MeOH, basic alumina added, and then concentrated under reduced pressure. The solid was loaded on to a silica column and the product eluted with 2:1 hexanes:EtOAc. Yield of alcohol **2** (4.4 g, 87%): ¹H NMR (300 MHz, CD₃OD) δ 7.07 (d, *J* = 8 Hz, 2H), 6.68 (d, *J* = 8 Hz, 2H), 4.02 (m, 1H), 2.44 (tt, *J* = 10, 2 Hz, 1H), 1.87 (m, 4H), 1.60 (m, 4H).

Step 2: To an ice-cold solution of alcohol **2** (0.5 g, 2.5 mmol) in THF (20 mL), under an N₂ atmosphere, was added Et₃N (1.0 mL, 7.2 mmol), followed by methanesulfonyl chloride (0.5 mL, 6.5 mmol). After 2 minutes, the reaction mixture was diluted with EtOAc and washed with 2N HCl, H₂O, saturated NaHCO₃, saturated NaCl, and dried (Na₂SO₄). Concentration under reduced pressure gave mesylate **3** (1.0 g, quant.), which was used without further purification: ¹H NMR (300 MHz, CD₃OD) δ 7.28 (d, *J* = 8 Hz, 2H), 7.20 (d, *J* = 8 Hz, 2H), 5.05 (m, 1H), 3.13 and 3.04 (both s, 3H), 2.60 (tt, *J* = 10, 2 Hz, 1H), 2.22 (m, 2H), 1.70 (m, 6H).

Step 3: To a solution of mesylate **3** (1.0 g, 2.5 mmol) in DMSO (5 mL) was added NaN₃ (0.5 g, 7.7 mmol). The reaction mixture was stirred at 50°C overnight. After cooling, the reaction mixture was diluted with EtOAc, washed with H₂O and saturated NaCl and dried (Na₂SO₄). Concentration under reduced pressure, followed by purification by flash chromatography (eluent 6:1 to 4:1 hexanes:EtOAc) gave the azide **4** (0.6 g, 75%): ¹H NMR (300 MHz, CDCl₃) δ 7.23 (m, 4H), 3.43 (tt, *J* = 10, 2 Hz, 1H), 3.33 (s, 3H), 2.54 (tt, *J* = 10, 2 Hz, 1H), 2.25 (m, 2H), 1.96 (m, 2H), 1.50 (m, 4H).

Step 4: To an ice-cold solution of azide **4** (6.85 g, 23.2 mmol) in THF (200 mL) was added LiAlH₄ (58 mL of a 1 M solution in Et₂O, 58 mmol). The


mixture was heated under reflux overnight. After cooling to 0°C, a mixture of 2 M NaOH (1.6 mL) and H₂O (5.1 mL) was added dropwise. The solids were removed by filtration and then boiled with first EtOH and then MeOH to extract any bound product. All of the organic solutions were combined and concentrated under reduced pressure. The crude product was taken up in EtOH and dried over 3 Å molecular sieves. Basic alumina was added to the ethanolic solution, and the solvent was removed under reduced pressure. The solid was loaded onto a silica column (eluent 8:2 CHCl₃:MeOH, 7:3 CHCl₃:MeOH, 80:18:2 CHCl₃:MeOH:NH₄OH, and 70:27:3 CHCl₃:MeOH:NH₄OH). The product was further purified by triturating with CHCl₃. Yield of amine 5 (2.77 g, 63%): ¹H NMR (300 MHz, CDCl₃) δ 7.02 (d, *J* = 8 Hz, 2H), 6.68 (d, *J* = 8 Hz, 2H), 2.48 and 2.28 (both tt, *J* = 10, 2 Hz, 1H), 1.96 and 1.85 (both br d, *J* = 10 Hz, 2H), 1.49 and 1.27 (both dddd, *J* = 10, 10, 10, 2 Hz, 2H).

EXAMPLE 1

(a) *cis*-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol

(b) *trans*-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol

(Magid-Abdel A.F., Carson K.G., Harris B.D., Maryanoff C.A., Shah R.D., *J. Org. Chem.*, 1996;61:3849)



To a stirred solution of 4-phenylbutylamine (3.00 g, 20.10 mmol) and 4-(4-hydroxyphenyl)cyclohexanone 1 (3.82 g, 20.10 mmol) in 1,2-dichloroethane (70 mL) was added sodium triacetoxyborohydride (5.96 g, 28.14 mmol), followed by glacial acetic acid (1.20 g, 20.10 mmol). The reaction mixture was stirred overnight. The solution was basified with 2N NaOH (20 mL) and extracted with EtOAc (500 mL). The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure. Purification by flash chromatography (silica, 9:4:1 CH₂Cl₂:MeOH:NH₄OH) gave (a) the *cis*-isomer : *cis*-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol (0.8 g, 12%): mp 128-131°C; IR (KBr): 3293, 2934,


1611 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.29 (m, 5H), 7.08 (d, $J = 10$ Hz, 2H), 6.72 (d, $J = 10$ Hz, 2H), 2.82 (m, 1H), 2.65 (tt, $J = 7, 3$ Hz, 2H), 2.65 (tt, $J = 7, 3$ Hz, 2H), 2.51 (m, 1H), 1.89-1.54 (m, 12H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.2, 142.3, 137.7, 128.2, 128.1, 127.9, 127.4, 125.5, 114.9, 51.2, 46.6, 42.4, 35.1, 30.0, 29.4, 28.9, 28.1; CI-MS (methane) (m/z): 324 $[\text{M} + \text{H}]^+$; HPLC: method A, 6.21 minutes (98.4%); method B, 12.38 minutes (99.7%); Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{NO} \cdot 0.33\text{H}_2\text{O}$: C, 80.20; H, 9.08; N, 4.25. Found: C, 80.08; H, 8.96; N, 4.16.

Yield of the *trans*-isomer (b) *trans*-4-[4-(4-phenylbutylamino)cyclohexyl]-phenol (0.2 g, 4%): mp 161-171°C; IR (KBr): 3275, 2924, 1611 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.31-7.20 (m, 5H), 7.07 (d, $J = 9$ Hz, 2H), 6.70 (d, $J = 9$ Hz, 2H), 2.64 (tt, $J = 4, 4$ Hz, 2H), 2.63 (tt, $J = 4, 4$ Hz, 2H), 2.58 (tt, $J = 10, 2$ Hz, 1H), 2.48 (tt, $J = 10, 2$ Hz, 1H), 2.06 (br d, $J = 10$ Hz, 2H), 1.85 (br d, $J = 10$ Hz, 2H), 1.63 (quint, $J = 4$ Hz, 2H), 1.58 (quint, $J = 4$ Hz, 2H), 1.49 (dddd, $J = 10, 10, 10, 2$ Hz, 2H), 1.41 (dddd, $J = 10, 10, 10, 2$ Hz, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 156.6, 143.7, 139.3, 129.6, 129.5, 128.7, 126.9, 116.2, 57.9, 47.6, 44.7, 36.9, 34.5, 33.9, 30.5, 30.2; CI-MS (methane) (m/z): 324 $[\text{M} + \text{H}]^+$; HPLC: method A, 6.17 minutes (96.0%); Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{NO}$: C, 81.69; H, 9.04; N, 4.33. Found: C, 81.41; H, 9.14; N, 4.30.

EXAMPLE 2

(a) *cis*-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol

(b) *trans*-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol



In a manner similar to Example 1, 3-phenylpropyl amine was allowed to react with 4-(4-hydroxyphenyl)cyclohexanone to give (1.4 g, 28%): (a) *cis*-4-[4-(3-phenylpropylamino)cyclohexyl]phenol: mp 115-123°C; IR (KBr): 3303, 2929, 1611 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.27-7.13 (m, 5H), 7.05 (d, $J = 9$ Hz, 2H), 6.72 (d, $J = 9$ Hz, 2H), 2.82 (m, 1H), 2.58-2.49 (m, 4H), 2.48 (m, 1H), 1.92-


1.56 (m, 10H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.2, 142.3, 137.7, 128.2, 128.1, 127.3, 125.5, 114.8, 51.2, 46.3, 42.4, 33.0, 30.1, 28.1; API-MS (m/z): 310 $[\text{M} + \text{H}]^+$; HPLC: method A, 5.99 minutes (99.2%); Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}$: C, 81.51; H, 8.79; N, 4.53. Found: C, 81.14; H, 8.88; N, 4.36.

5 And the *trans*-isomer (b) IUPAC: *trans*-4-[4-(3-phenylpropylamino)cyclohexyl]phenol (0.8 g, 15%): mp 154-157°C; IR (KBr): 3268, 2925, 1612 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.28-7.13 (m, 5H), 7.01 (d, $J = 9$ Hz, 2H), 6.68 (d, $J = 9$ Hz, 2H), 2.71 (tt, $J = 8, 8$ Hz, 2H), 2.69 (tt, $J = 8, 8$ Hz, 2H), 2.58 (tt, $J = 9, 2$ Hz, 1H), 2.41 (tt, $J = 9, 2$ Hz, 1H), 2.04 (br d, $J = 9$ Hz, 2H), 1.89 (br d, $J = 9$ Hz, 2H), 1.87 (quint, $J = 8$ Hz, 2H), 1.48 (dddd, $J = 9, 9, 9, 2$ Hz, 2H), 1.39 (dddd, $J = 9, 9, 9, 2$ Hz, 2H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.3, 142.2, 137.1, 128.2, 127.9, 127.3, 125.6, 114.9, 56.2, 45.8, 42.7, 33.1, 32.9, 31.6; API-MS (m/z): 310 $[\text{M} + \text{H}]^+$; HPLC: method A, 5.89 minutes (99.7%); method B, 11.37 minutes (96.5%); Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{NO} \cdot 0.33\text{H}_2\text{O}$: C, 79.96; H, 8.84; N, 4.44. Found: C, 79.72; H, 8.93; N, 4.34.

EXAMPLE 3

(a) *cis*-4-(4-Phenethylaminocyclohexyl)phenol and

(b) *trans*-4-(4-Phenethylaminocyclohexyl)phenol.



20 Yield of the *cis*-isomer (a) *cis* 4-(4-phenethylaminocyclohexyl)-phenol (3.0 g, 44%): mp 155-160°C; IR (KBr): 3288, 2935, 1614 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.11 (br s, 1H), 7.28-7.18 (m, 5H), 6.96 (d, $J = 8$ Hz, 2H), 6.65 (d, $J = 8$ Hz, 2H), 2.82 (m, 1H), 2.48 (m, 1H), 1.71-1.61 (m, 6H), 1.57-1.48 (m, 6H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.1, 141.2, 137.7, 128.5, 127.3, 125.7, 114.8, 50.7, 48.4, 42.3, 36.1, 30.0, 27.9; API-MS (m/z): 296 $[\text{M} + \text{H}]^+$; HPLC: method B, 11.02 minutes (97.2%); Anal. Calcd for $\text{C}_{20}\text{H}_{25}\text{NO} \cdot 0.50\text{H}_2\text{O}$: C, 78.91; H, 8.61; N, 4.60. Found: C, 79.20; H, 8.39; N, 4.44.


Yield of the *trans*-isomer (b) *trans*-4-(4-phenethylaminocyclohexyl)

phenol (2.7 g, 41%): mp 147-149°C; IR (KBr): 3276, 2916, 1611 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.31-7.15 (m, 5H), 6.99 (d, $J = 9$ Hz, 2H), 6.68 (d, $J = 9$ Hz, 2H), 2.85 (tt, $J = 5, 5$ Hz, 2H), 2.84 (tt, $J = 5, 5$ Hz, 2H), 2.51 (tt, $J = 12, 2$ Hz, 1H), 2.49 (tt, $J = 12, 2$ Hz, 1H), 2.07 (br d, $J = 12$ Hz, 2H), 1.86 (br d, $J = 12$ Hz, 2H), 1.48 (dddd, $J = 12, 12, 12, 2$ Hz, 2H), 1.24 (dddd, $J = 12, 12, 12, 2$ Hz, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 130.2, 130.1, 129.1, 127.8, 116.6, 58.2, 37.4, 34.9, 34.6; API-MS (m/z): 296 $[\text{M} + \text{H}]^+$; HPLC: method A, 6.40 minutes (94.4%); Anal. Calcd for $\text{C}_{20}\text{H}_{25}\text{NO}$: C, 81.31; H, 8.53; N, 4.74. Found: C, 81.24; H, 8.54; N, 4.52.

EXAMPLE 4

(a) *cis*-4-(4-Benzylaminocyclohexyl)phenol and

(b) *trans*-4-(4-Benzylaminocyclohexyl)phenol



Yield of the *cis*-isomer (a) *cis*-4-(4-benzylamino-cyclohexyl)-phenol

(1.3 g, 21%): mp 107-110°C; IR (KBr): 3292, 2926, 1610 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.09 (br s, 1H), 7.37-7.19 (m, 5H), 7.03 (d, $J = 9$ Hz, 2H), 6.65 (d, $J = 9$ Hz, 2H), 3.34 (s, 2H), 2.76 (m, 1H), 2.38 (m, 1H), 1.77-1.73 (m, 4H), 1.51-1.42 (m, 4H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.2, 141.6, 137.8, 127.9, 127.9, 126.3, 114.9, 50.4, 50.1, 30.0, 28.1; API-MS (m/z): 282 $[\text{M} + \text{H}]^+$; HPLC: method A, 5.38 minutes (97.9%); method B, 5.30 minutes (97.9%); Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{NO} \cdot 0.125\text{H}_2\text{O}$: C, 80.45; H, 8.26; N, 4.94. Found: C, 80.52; H, 8.10; N, 4.84.

Yield of the *trans*-isomer (b) *trans*-4-(4-benzylaminocyclohexyl)phenol


(0.8 g, 12%): mp 168-172°C; IR (KBr): 3279, 2918, 1613 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.36-7.24 (m, 5H), 7.01 (d, $J = 8$ Hz, 2H), 6.68 (d, $J = 8$ Hz, 2H), 3.80 (s, 2H), 2.48 (tt, $J = 13, 3$ Hz, 1H), 2.43 (tt, $J = 13, 3$ Hz, 1H), 2.10 (br d, $J = 13$ Hz, 2H), 1.84 (br d, $J = 13$ Hz, 2H), 1.46 (dddd, $J = 13, 13, 13, 2$ Hz, 2H).

3 Hz, 2H), 1.44 (dddd, $J = 13, 13, 13, 3$ Hz, 2H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.3, 137.2, 127.9, 127.8, 127.3, 126.2, 114.9, 55.4, 50.0, 42.7, 33.3, 32.9; API-MS (m/z): 282 $[\text{M} + \text{H}]^+$; HPLC: method A, 5.13 minutes (97.7%); method B, 5.07 minutes (90.8%); Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{NO} \cdot 0.125\text{H}_2\text{O}$: C, 80.45; H, 8.26; N, 4.94. Found: C, 80.24; H, 8.27; N, 4.92.

EXAMPLE 5

(a) *cis*-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol

(b) *trans*-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol



The *cis*-isomer (a) *cis*-4-{4-[2-(4-fluoro-phenyl)-ethylamino]-cyclohexyl}-phenol was isolated as the HCl salt (1.2 g, 20%): mp 234-237°C; IR (KBr): 3252, 2941, 1612 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.06 (br s, 1H), 7.34 (dd, $J = 8, 6$, Hz, 2H), 7.19 (dd, $J = 8, 6$ Hz, 2H), 7.16 (d, $J = 8$ Hz, 2H), 6.69 (d, $J = 8$ Hz, 2H), 3.11 (m, 4H), 3.08 (m, 1H), 2.51 (m, 1H), 2.02 (m, 4H), 1.72 (m, 2H), 1.59 (m, 2H); CI-MS (methane) (m/z): 314 $[\text{M} + \text{H}]^+$; HPLC: method A, 5.47 minutes (99.3%); Anal. Calcd for $\text{C}_{20}\text{H}_{24}\text{FNO} \cdot \text{HCl}$: C, 68.66; H, 7.20; N, 4.00. Found: C, 68.55; H, 7.41; N, 4.36.

The *trans*-isomer (b) *trans*-4-{4-[2-(4-fluorophenyl)ethylamino]-cyclohexyl}phenol was isolated as the HCl salt (0.2 g, 5%): mp 239-242°C; IR (KBr): 3252, 2941, 1612 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.16 (s, 1H), 7.34 (dd, $J = 7, 6$, Hz, 2H), 7.17 (dd, $J = 7, 6$ Hz, 2H), 7.00 (d, $J = 9$ Hz, 2H), 6.69 (d, $J = 9$ Hz, 2H), 3.16 (m, 4H), 3.13 (m, 1H), 2.98 (m, 2H), 2.48 (m, 1H), 2.15 (br d, $J = 8$ Hz, 2H), 1.82 (br d, $J = 8$ Hz, 2H), 1.44 (dddd, $J = 8, 8, 8, 2$, 4H); API-MS (m/z): 324 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{24}\text{FNO}$, 324.2327; found, 324.2324; HPLC: method A, 7.61 minutes (96.5%); method B, 13.60 minutes (99.9%); Anal. Calcd for $\text{C}_{20}\text{H}_{24}\text{FNO} \cdot \text{HCl} \cdot \text{H}_2\text{O}$: C, 65.30; H, 7.40; N, 3.81. Found: C, 65.59; H, 7.35; N, 3.75.


EXAMPLE 6

(a) *trans*-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol

(b): *cis*-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol


(c) *trans*-4-[4-((*R*)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol

5 (d) *trans*-4-[4-((*S*)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol




The *cis*-isomer (a) *cis*-4-[4-(1-methyl-3-phenylpropylamino)cyclohexyl]phenol was isolated as the HCl salt (1.9 g, 40%): mp 204-214°C; IR (KBr): 3250, 2942, 1613 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.17 (br s, 1H), 7.31-7.20 (m, 5H), 7.15 (d, *J* = 9 Hz, 2H), 6.69 (d, *J* = 9 Hz, 2H), 3.32 (m, 1H), 2.74 (m, 1H), 2.57 (m, 1H), 2.19-1.93 (m, 2H), 1.74-1.52 (m, 9H), 1.33 (d, *J* = 7 Hz, 3H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HPLC: method A, 6.14 minutes (98.1%); method B, 6.16 minutes (97.9%); Anal. Calcd for C₂₂H₂₉NO•HCl: C, 73.41; H, 8.40; N, 3.89. Found: C, 73.17; H, 8.45; N, 3.79.

15 The *trans*-isomer (b) *trans*-4-[4-(1-methyl-3-phenylpropylamino)-cyclohexyl]phenol was isolated as the HCl salt (1.2 g, 21%): mp 169-176°C; IR (KBr): 3260, 2924, 1612 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.08 (s, 1H), 7.28-7.12 (m, 5H), 6.97 (d, *J* = 8 Hz, 2H), 6.64 (d, *J* = 8 Hz, 2H), 2.73 (tt, *J* = 12, 3 Hz, 1H), 2.64 (t, *J* = 7 Hz, 2H), 2.54 (m, 1H), 2.45 (tt, *J* = 12, 3 Hz, 1H), 1.93-1.04 (m, 10H), 1.01 (d, *J* = 7 Hz, 3H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HPLC: method A, 5.64 minutes (99.8%); method B, 6.14 minutes (98.1%); Anal. Calcd for C₂₂H₂₉NO•0.125H₂O: C, 81.12; H, 9.05; N, 4.30. Found: C, 81.09; H, 9.04; N, 4.19.




(c) *trans*-4-[4-((*R*)-1-methyl-3-phenylpropylamino)cyclohexyl] phenol was isolated as the free base (0.3 g, 6%): mp 152-160°C; IR (KBr): 3265, 2926, 1616 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.08 (s, 1H), 7.28-7.12 (m, 5H), 6.97 (d, *J* = 8 Hz, 2H), 6.64 (d, *J* = 8 Hz, 2H), 2.73 (tt, *J* = 12, 3 Hz, 1H), 2.64 (t, *J* = 7 Hz, 2H), 2.54 (m, 1H), 2.45 (tt, *J* = 12, 3 Hz, 1H), 1.93-1.04 (m, 10H), 1.01 (d, *J* = 7 Hz, 3H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HPLC: method A, 7.90 minutes (99.5%); method B, 14.46 minutes (97.6%); Anal. Calcd for C₂₂H₂₉NO: C, 81.69; H, 9.04; N, 4.33. Found: C, 81.65; H, 9.25; N, 4.15.



(d) *trans*-4-[4-((*S*)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol was isolated as the free base (0.35 g, 7%): mp 165-170°C; IR (KBr): 3268, 2926, 1612 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.08 (s, 1H), 7.28-7.12 (m, 5H), 6.97 (d, *J* = 8 Hz, 2H), 6.64 (d, *J* = 8 Hz, 2H), 2.73 (tt, *J* = 12, 3 Hz, 1H), 2.64 (t, *J* = 7 Hz, 2H), 2.54 (m, 1H), 2.45 (tt, *J* = 12, 3 Hz, 1H), 1.93-1.04 (m, 10H), 1.01 (d, *J* = 7 Hz, 3H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₂H₂₉NO, 324.2327; found, 324.2324; HPLC: method A, 7.87 minutes (97.9%); method B, 11.22 minutes (96.9%); Anal. Calcd for C₂₂H₂₉NO: C, 81.69; H, 9.04; N, 4.33. Found: C, 81.35; H, 9.01; N, 4.30.

EXAMPLE 7

(a) *cis*-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol
 (b) *trans*-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol



The *cis*-isomer (a) *cis*-4-{4-[(pyridin-3-ylmethyl)amino] cyclohexyl}-phenol was isolated as the *bis*-HCl salt (1.85 g, 36%): mp 151-162°C; IR (KBr):

2936, 1612, 1516 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 9.21 (s, 1H), 8.95 (d,


$J = 8, 6$ Hz, 1H), 8.88 (d, $J = 8$ Hz, 1H), 8.18 (dd, $J = 8, 6$ Hz, 1H), 7.19 (d, $J = 8$ Hz, 2H), 6.72 (d, $J = 8$ Hz, 2H), 4.59 (s, 2H), 3.61-3.55 (m, 1H), 2.79-2.59 (m, 1H), 2.15-1.95 (m, 6H), 1.90-1.78 (m, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 156.8, 149.9, 145.1, 143.8, 137.2, 133.6, 129.2, 128.8, 116.3, 57.95, 46.7, 41.3, 29.1, 27.6; CI-MS (methane) (m/z): 283 $[\text{M} + \text{H}]^+$; HPLC: method C, 10.76 minutes (99.6%); Anal. Calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O} \cdot 2\text{HCl}$: C, 60.85; H, 6.81; N, 7.88. Found: C, 60.42; H, 6.94; N, 7.69.

The *trans*-isomer (b) *trans*-4-{4-[(pyridin-3-ylmethyl) amino]cyclohexyl}-phenol was isolated as the *bis*-HCl salt (0.18 g, 4%): mp 309-312°C; IR (KBr): 3169, 2940, 1613, 1516 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 9.08 (s, 1H), 8.93 (d, $J = 6$ Hz, 1H), 8.70 (d, $J = 8$ Hz, 1H), 8.11 (dd, $J = 8, 6$ Hz, 1H), 7.05 (d, $J = 8$ Hz, 2H), 6.71 (d, $J = 8$ Hz, 2H), 4.55 (s, 2H), 3.36 (tt, $J = 10, 2$ Hz, 1H), 2.52 (tt, $J = 10, 2$ Hz, 1H), 2.36 (br d, $J = 10$ Hz, 2H), 2.02 (br d, $J = 10$ Hz, 2H), 1.60 (dddd, 10, 10, 10, 2 Hz, 4H); CI-MS (methane) (m/z): 283 $[\text{M} + \text{H}]^+$; HPLC: method C, 6.26 minutes (99.9%); Anal. Calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O} \cdot 2\text{HCl}$: C, 60.85; H, 6.81; N, 7.88. Found: C, 60.92; H, 6.85; N, 7.81.

EXAMPLE 8

(a) *cis*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol

(b) *trans*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol




The *cis*-isomer (a) *cis*-4-{4-[2-(4-methoxyphenyl) ethylamino]-cyclohexyl}phenol was isolated as the free base (1.5 g, 34%): mp 145-148°C; IR (KBr): 3296, 2930, 1612 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.06 (br s, 1H), 7.14 (d, $J = 9$ Hz, 2H), 6.93 (d, $J = 9$ Hz, 2H), 6.84 (d, $J = 9$ Hz, 2H), 6.63 (d, $J = 9$ Hz, 2H), 3.43 (s, 3H), 2.78 (m, 1H), 2.66 (m, 4H), 2.33 (m, 1H), 1.72-1.35 (m, 8H); CI-MS (methane) (m/z): 326 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}_2$, 326.2120; found, 326.2118; HPLC: method A,

5.81 minutes (99.7%); method B, 11.12 minutes (99.2%); Anal. Calcd for $C_{21}H_{27}NO_2 \cdot 0.25H_2O$: C, 76.44; H, 8.40; N, 4.25. Found: C, 76.38; H, 8.33; N, 4.22.

The *trans*-isomer (b) IUPAC: *trans*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol was isolated as the free base (1.0 g, 18%): mp 146-152°C; IR (KBr): 3286, 2926, 1612 cm^{-1} ; 1H NMR (300 MHz, DMSO- d_6) δ 9.09 (s, 1H), 7.14 (d, $J = 9$ Hz, 2H), 6.99 (d, $J = 9$ Hz, 2H), 6.84 (d, $J = 9$ Hz, 2H), 6.65 (d, $J = 9$ Hz, 2H), 3.45 (s, 3H), 2.61 (tt, $J = 7, 7$ Hz, 2H), 2.60 (tt, $J = 7, 7$ Hz, 2H), 2.42 (tt, $J = 9, 2$ Hz, 1H), 2.42 (tt, $J = 9, 2$ Hz, 1H), 1.93 (br d, $J = 9$ Hz, 2H), 1.74 (br d, $J = 9$ Hz, 2H), 1.35 (dddd, $J = 9, 9, 9, 2$ Hz, 2H), 1.11 (dddd, $J = 9, 9, 9, 2$ Hz, 2H); CI-MS (methane) (m/z): 326 $[M + H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{21}H_{27}NO_2$, 326.2120; found, 326.2129; HPLC: method A, 5.69 minutes (97.9%); method B, 11.15 minutes (97.8%); Anal. Calcd for $C_{21}H_{27}NO_2 \cdot 0.25H_2O$: C, 76.44; H, 8.40; N, 4.25. Found: C, 76.38; H, 8.23; N, 4.24.

EXAMPLE 9

4-[4-(5-Phenylpentylamino)cyclohexyl]phenol




4-[4-(5-Phenylpentylamino)cyclohexyl]phenol was isolated as the HCl salt (0.5 g, 7%): mp 252-260°C; IR (KBr): 3243, 2937, 1613 cm^{-1} ; 1H NMR (300 MHz, DMSO- d_6) δ 9.16 (s, 1H), 7.31-7.14 (m, 5H), 6.97 (d, $J = 9$ Hz, 2H), 6.66 (d, $J = 9$ Hz, 2H), 3.01 (m, 1H), 2.96 (m, 2H), 2.67 (t, $J = 7$ Hz, 2H), 2.39 (m, 2H), 2.17 (m, 2H), 1.83 (m, 2H), 1.73-1.38 (m, 10H); CI-MS (methane) (m/z): 338 $[M + H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{23}H_{31}NO$, 338.2484; found, 338.2480; HPLC: method A, 6.61 minutes (93.7%); method B, 12.25 minutes (98.7%); Anal. Calcd for $C_{23}H_{31}NO \cdot HCl \cdot 0.25H_2O$: C, 72.99; H, 8.66; N, 3.70. Found: C, 72.75; H, 8.62; N, 3.61.

EXAMPLE 10

(a) *cis*-4-[4-((*R*)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]phenol

(b) *trans*-4-[4-((*R*)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]phenol



The *cis*-isomer (a) *cis*-4-[4-((*R*)-1-hydroxymethyl-2-phenylethylamino)-cyclohexyl]phenol was isolated as the HCl salt (0.44 g, 10%): mp 194-198°C; IR (KBr): 3274, 1613, 1516 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.40-7.27 (m, 5H), 7.14 (d, $J = 9$ Hz, 2H), 6.73 (d, $J = 9$ Hz, 2H), 3.78-3.69 (m, 1H), 3.58-3.49 (m, 3H), 3.13-2.97 (m, 2H), 2.82-2.75 (m, 1H), 2.11-1.76 (m, 8H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 155.4, 137.1, 135.7, 129.3, 128.5, 128.0, 126.7, 115.0, 58.9, 57.5, 51.9, 33.5, 27.4, 26.0, 26.0; CI-MS (methane) (m/z): 326 [$\text{M} + \text{H}$] $^+$; HRMS-API (m/z): [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}_2$, 326.2120; found, 326.2121; HPLC: method A, 5.53 minutes (99.2%); method B, 10.36 minutes (99.7%); Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}_2 \cdot \text{HCl} \cdot 0.25\text{H}_2\text{O}$: C, 68.84; H, 7.84; N, 3.82. Found: C, 69.07; H, 7.85; N, 3.73.


The *trans*-isomer (b) *trans*-4-[4-((*R*)-1-hydroxymethyl-2-phenylethylamino)cyclohexyl]phenol was isolated as the HCl salt (0.28 g, 7%): mp 191-198°C; IR (KBr): 3316, 2950, 1615, 1515 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.41-7.26 (m, 5H), 7.03 (d, $J = 9$ Hz, 2H), 6.70 (d, $J = 9$ Hz, 2H), 3.73 (br d, $J = 12$ Hz, 1H), 3.60-3.50 (m, 2H), 3.31-3.23 (m, 1H), 3.01-2.98 (m, 2H), 2.55-2.45 (m, 1H), 2.30-2.20 (m, 2H), 2.01-1.93 (m, 2H), 1.68-1.48 (m, 4H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 129.2, 128.4, 127.2, 126.6, 115.0, 57.6, 57.1, 53.5, 41.5, 33.5, 31.9, 28.5, 28.3; CI-MS (methane) (m/z): 326 [$\text{M} + \text{H}$] $^+$; HRMS-API (m/z): [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}_2$, 326.2120; found, 326.2122; HPLC: method A, 5.43 minutes (98.2%); method B, 10.03 minutes (98.3%); Anal. Calcd

for $C_{21}H_{27}NO_2 \cdot HCl \cdot 0.25H_2O$: C, 68.84; H, 7.84; N, 3.82. Found: C, 68.61; H, 8.07; N, 3.66.

EXAMPLE 11

(a) *cis*-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol

5 (b) *trans*-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol




The *cis*-isomer (a) *cis*-4-[4-(2-phenoxyethylamino)cyclohexyl] phenol was isolated as the free base (1.1 g, 31%): mp 165-172°C; IR (KBr): 3261, 2933, 1601 cm^{-1} ; 1H NMR (300 MHz, DMSO- d_6) δ 9.07 (br s, 1H), 7.39 (t, $J = 7$, 7 Hz, 3H), 7.03 (t, $J = 7$, 7 Hz, 2H), 6.98 (d, $J = 9$ Hz, 2H), 6.68 (d, $J = 9$ Hz, 2H), 4.05 (t, $J = 6$, 6 Hz, 2H), 2.87 (m, 2H), 2.85 (m, 1H), 2.40 (m, 1H), 1.79-1.43 (m, 8H); CI-MS (methane) (m/z): 312 $[M + H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{20}H_{25}NO_2$, 312.1963; found, 312.1967; HPLC: method A, 5.51 minutes (98.7%); method B, 9.95 minutes (97.3%); Anal. Calcd for $C_{20}H_{25}NO_2 \cdot 0.125H_2O$: C, 76.58; H, 8.11; N, 4.42. Found: C, 76.62; H, 8.04; N, 4.39.

The *trans*-isomer (b) *trans*-4-[4-(2-phenoxyethylamino) cyclohexyl]-phenol was isolated as the free base (0.5 g, 10%): mp 190-196°C; IR (KBr): 3245, 2926, 1602 cm^{-1} ; 1H NMR (300 MHz, DMSO- d_6) δ 9.09 (s, 1H), 7.29 (dd, $J = 9$, 9 Hz, 2H), 6.99 (d, $J = 9$ Hz, 2H), 6.93 (d, $J = 9$ Hz, 2H), 6.64 (d, $J = 9$ Hz, 2H), 4.00 (t, $J = 5$ Hz, 2H), 2.92 (t, $J = 5$ Hz, 2H), 2.51 (tt, $J = 11$, 2 Hz, 2H), 2.49 (tt, $J = 11$, 2 Hz, 2H), 2.01 (br d, $J = 11$ Hz, 2H), 1.74 (br d, $J = 11$ Hz, 2H), 1.42 (dddd, $J = 11$, 11, 11, 2 Hz, 2H), 1.14 (dddd, $J = 11$, 11, 11, 2 Hz, 2H); CI-MS (methane) (m/z): 312 $[M+H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{20}H_{25}NO_2$, 312.1963; found, 312.1953; HPLC: method A, 5.36 minutes (96.7%); method B, 10.02 minutes (97.3%); Anal. Calcd for $C_{20}H_{25}NO_2 \cdot 0.33H_2O$: C, 79.96; H, 8.84; N, 4.44. Found: C, 79.82; H, 8.84; N, 4.14.

EXAMPLE 12

(a) *cis*-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol

(b) *trans*-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol




5 The *cis*-isomer (a) *cis*-4-[4-(3-pyridin-4-ylpropylamino) cyclohexyl]-phenol was isolated as the *bis*-HCl salt (0.56 g, 11%): mp 261-268°C; IR (KBr): 3158, 2942, 1636, 1610, 1515 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 8.78 (d, $J = 6$ Hz, 2H), 8.04 (d, $J = 6$ Hz, 2H), 7.15 (d, $J = 8$ Hz, 2H), 6.72 (d, $J = 8$ Hz, 2H), 3.47-3.38 (m, 1H), 3.19-3.04 (m, 4H), 2.77-2.64 (m, 2H), 2.29-2.14 (m, 2H),
10 2.09-1.71 (m, 7H); ^{13}C NMR (75 MHz, CD_3OD) δ 164.5, 156.8, 142.6, 137.5, 129.3, 128.8, 116.4, 56.7, 46.3, 41.6, 33.9, 29.0, 27.7, 27.2; CI-MS (methane) (m/z): 311 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}$, 311.2123; found, 311.2115; HPLC: method C, 5.66 minutes (97.8%); method D, 13.03 minutes (97.8%); Anal. Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O} \cdot 2\text{HCl} \cdot 0.25\text{H}_2\text{O}$: C, 61.93; H, 7.41; N, 7.22. Found: C, 61.74; H, 7.51; N, 7.06.

15 The *trans*-isomer (b) *trans*-4-[4-(3-pyridin-4-ylpropylamino) cyclohexyl]-phenol was isolated as the maleate salt (0.20 g, 4%): mp 192-196°C; IR (KBr): 2937, 1516 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 8.46 (d, $J = 6$, Hz, 2H), 7.34 (d, $J = 6$, Hz, 2H), 7.04 (d, $J = 8$ Hz, 2H), 6.70 (d, $J = 8$ Hz, 2H), 6.25 (s, 2H), 3.17 (tt, $J = 10$, 2 Hz, 1H), 3.09 (t, $J = 8$ Hz, 2H), 2.88 (t, $J = 8$ Hz, 2H),
20 2.47 (tt, $J = 10$, 2 Hz, 1H), 2.47 (d, $J = 8$ Hz, 2H), 2.10-1.91 (m, 4H), 1.55 (dddd, 10, 10, 10, 2 Hz, 4H); CI-MS (methane) (m/z): 311 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}$, 311.2123; found, 311.2110; HPLC [free base]: method C, 6.68 minutes (99.1%); Anal. Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O} \cdot \text{C}_4\text{H}_4\text{O}_4$: C, 67.59; H, 7.09; N, 6.57. Found: C, 67.21; H, 7.26; N, 6.33.

EXAMPLE 13

trans-4-[4-((*S*)-1-Methyl-2-phenylethylamino)cyclohexyl]phenol




The *trans*-isomer *trans*-4-[4-((*S*)-1-methyl-2-phenylethylamino)cyclohexyl]phenol was isolated as the free base (0.7 g, 12%): mp 183-187°C; IR (KBr): 3287, 2922, 1612 cm^{-1} ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.31-7.15 (m, 5H), 6.96 (d, $J = 8$ Hz, 2H), 6.68 (d, $J = 8$ Hz, 2H), 2.82-2.64 (m, 3H), 2.49 (tt, $J = 12$, 3 Hz, 1H), 2.48 (tt, $J = 12$, 3 Hz, 1H), 1.94 (br d, $J = 12$ Hz, 2H), 1.39 (br d, $J = 12$ Hz, 2H), 1.38 (dddd, $J = 12$, 12, 12, 3 Hz, 2H), 1.19 (d, $J = 13$ Hz, 3H), 1.09 (dddd, $J = 12$, 12, 12, 3 Hz, 2H); CI-MS (methane) (m/z): 310 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}$, 310.2171; found, 310.2166; HPLC: method A, 5.47 minutes (99.8%); method B, 10.49 minutes (99.7%); Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{NO} \cdot 0.33\text{H}_2\text{O}$: C, 79.96; H, 8.84; N, 4.44. Found: C, 79.82; H, 8.84; N, 4.14.

EXAMPLE 14

(a) *cis*-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol

(b) *trans*-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol



The *cis*-isomer (a) *cis*-4-[4-(3-pyridin-3-ylpropylamino)cyclohexyl]phenol was isolated as the maleate salt (2.05 g, 32%): mp 158-162°C; IR (KBr): 2943, 1578, 1516 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 8.45 (s, 1H), 8.41 (d, $J = 5$ Hz, 1H), 7.74 (d, $J = 8$ Hz, 1H), 7.41 (dd, $J = 8$, 5 Hz, 1H), 7.11 (d, $J = 8$ Hz, 2H), 6.72 (d, $J = 8$ Hz, 2H), 6.25 (s, 2H), 3.41-3.55 (m, 1H), 3.09 (t, $J = 8$ Hz, 2H), 2.78 (t, $J = 8$ Hz, 2H), 2.75-2.68 (m, 1H), 2.03 (d, $J = 8$ Hz, 2H), 1.95-1.77 (m, 8H); ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ 167.1, 155.4, 149.4, 147.4, 136.12, 135.8, 135.6, 127.7, 123.5, 114.9, 53.5, 44.3, 29.0, 27.1, 26.9, 25.8; CI-MS (methane) (m/z): 311 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}$,


311.2123; found, 311.2111; HPLC [free base]: method C, 6.55 minutes (99.7%), method D; 8.28 minutes (98.6%); Anal. Calcd for $C_{20}H_{26}N_2O \cdot C_4H_4O_4 \cdot 0.25H_2O$: C, 66.88; H, 7.13; N, 6.50. Found: C, 66.90; H, 7.04; N, 6.32.

- 5 The *trans*-isomer (b) *trans*-4-[4-(3-pyridin-3-ylpropylamino)cyclohexyl]phenol was isolated as the maleate salt (0.18 g, 3%): mp 175-180 °C; IR (KBr): 2938, 1617, 1576, 1516 cm^{-1} ; 1H NMR (300 MHz, CD_3OD) δ 8.45 (s, 1H), 8.42 (d, $J = 5$ Hz, 1H), 7.76 (d, $J = 8$ Hz, 1H), 7.41 (dd, $J = 8, 5$ Hz, 1H), 7.03 (d, $J = 8$ Hz, 2H), 6.70 (d, $J = 8$ Hz, 2H), 6.24 (s, 2H), 3.21-3.05 (m, 1H), 3.09 (t, $J = 8$ Hz, 2H), 2.80 (t, $J = 8$ Hz, 2H), 2.55-2.44 (m, 1H), 2.20 (d, $J = 8$ Hz, 2H), 2.10-1.91 (m, 4H), 1.67-1.45 (m, 4H); CI-MS (methane) (m/z): 311 $[M + H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{20}H_{26}N_2O$, 311.2123; found, 311.2128; HPLC [free base]: method C, 7.78 minutes (99.3%); method D, 7.24 minutes (99.3%); Anal. Calcd for $C_{20}H_{26}N_2O \cdot C_4H_4O_4 \cdot 0.25H_2O$: C, 66.88; H, 7.13; N, 6.50. Found: C, 66.96; H, 7.10; N, 6.30.

EXAMPLE 15

(a) *cis*-4-[4-(3-Pyridin-2-ylpropylamino)cyclohexyl]phenol

(b) *trans*-4'-(3-Pyridin-2-ylpropylamino)cyclohexylphenol



- 20 The *cis*-isomer (a) *cis*-4-[4-(3-pyridin-2-ylpropylamino) cyclohexyl]-phenol was isolated as the maleate salt (1.1 g, 14%): mp 137-140°C; IR (KBr): 2948, 1581, 1516 cm^{-1} ; 1H NMR (300 MHz, CD_3OD) δ 8.47 (d, $J = 5$ Hz, 1H), 7.80 (t, $J = 6$ Hz, 1H), 7.36 (d, $J = 8$ Hz, 1H), 7.12 (d, $J = 8$ Hz, 2H), 6.72 (d, $J = 8$ Hz, 2H), 6.25 (s, 2H), 3.42-3.36 (m, 1H), 3.13 (t, $J = 8$ Hz, 2H), 2.95 (t, $J = 8$ Hz, 2H), 2.76-2.68 (m, 1H), 2.18-2.07 (m, 2H), 2.00-1.75 (m, 8H); ^{13}C NMR (75 MHz, $DMSO-d_6$) δ 167.2, 159.9, 155.4, 148.9, 136.7, 135.6, 127.6, 122.9, 121.5, 114.9, 53.4, 44.6, 34.1, 27.1, 25.9, 25.1; CI-MS (methane) (m/z): 311 $[M + H]^+$; HPLC [free base]: method C, 8.67 minutes (96.4%); method D,


12.70 minutes (97.9%); Anal. Calcd for $C_{20}H_{26}N_2O \cdot C_4H_4O_4$: C, 67.59; H, 7.09; N, 6.57. Found: C, 67.51; H, 7.07; N, 6.54.

The *trans*-isomer (b) *trans*-4'-(3-Pyridin-2-ylpropylamino) cyclohexyl]-phenol was isolated as the maleate salt (0.54 g, 7%): mp 167-169°C; IR (KBr):

2940, 1576, 1516 cm^{-1} ; 1H NMR (300 MHz, CD_3OD) δ 8.49 (d, $J = 5$ Hz, 1H), 7.80 (t, $J = 6$ Hz, 1H), 7.36 (d, $J = 8$ Hz, 1H), 7.30 (t, $J = 8$ Hz, 1H), 7.03 (d, $J = 8$ Hz, 2H), 6.70 (d, $J = 8$ Hz, 2H), 6.25 (s, 2H), 3.21-3.09 (m, 3H), 2.93 (t, $J = 8$ Hz, 2H), 2.54-2.53 (m, 1H), 2.30-1.90 (m, 6H), 1.65-1.46 (m, 4H); CI-MS (methane) (m/z): 311 $[M + H]^+$; HPLC [free base]: method C, 4.87 minutes (95.7%); Anal. Calcd for $C_{20}H_{26}N_2O \cdot C_4H_4O_4$: C, 67.59; H, 7.09; N, 6.57. Found: C, 67.39; H, 7.13; N 6.37.

EXAMPLE 16


IUPAC: *trans*-*N*-Benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]acetamide



To *trans*-4-(4-benzylaminocyclohexyl)phenol (296 mg, 1.05 mmol) in 2N NaOH (5 mL) was added excess acetic anhydride. After 1 hour, the reaction mixture was poured into EtOAc (50 mL). The organic layer was dried (Na_2SO_4) and concentrated under reduced pressure. Purification by flash chromatography (silica, 9:4:1 CH_2Cl_2 :MeOH: NH_4OH) gave *trans*-*N*-benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]acetamide (170 mg, 21%) as a 50:50 mixture of rotomers: mp 227-235°C; IR (KBr): 3200, 2929, 1650, 1612 cm^{-1} ; 1H NMR (300 MHz, $DMSO-d_6$) δ 9.10 (s, 0.5H), 9.09 (s, 0.5H), 7.36-7.17 (m, 5H), 6.97 (d, $J = 9$ Hz, 2H), 6.65 (d, $J = 9$ Hz, 1H), 6.64 (d, $J = 9$ Hz, 1H), 4.57 (s, 1 H), 4.51 (s, 1H), 4.42 (m, 0.5H), 3.84 (m, 0.5H), 2.42-2.39 (m, 1H), 2.21 (s, 1.5H), 1.97 (s, 1.5H), 1.75-1.47 (m, 8H); CI-MS (methane) (m/z): 324 $[M + H]^+$; HPLC: method A, 8.79 minutes (97.4%); Anal. Calcd for $C_{21}H_{25}NO_2$: C, 77.99; H, 7.79; N, 4.33. Found: C, 77.61; H, 7.76; N 4.21.


42

EXAMPLE 17

(a) *trans*-*N*-[4-(4-Hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)acetamide

In a manner similar to Example 16, *trans*-4-[4-(3-phenylpropylamino)cyclohexyl]phenol was allowed to react with acetic anhydride to give *trans*-*N*-[4-(4-hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl) acetamide. Yield (90 mg, 2%): mp 175-180°C; IR (KBr): 3240, 2929, 1620, 1590 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.11 (s, 1H), 7.30-7.17 (m, 5H), 7.00 (d, *J* = 9 Hz, 2H), 6.69 (dd, *J* = 9, 2 Hz, 2H), 3.37 (m, 1H), 3.25 (m, 4H), 2.61 (m, 2H), 2.41 (m, 1H), 2.10 (s, 3H), 1.87-1.75 (m, 4H), 1.72-1.46 (m, 4H); CI-MS (methane) (*m/z*): 352 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₃H₂₉NO₂, 352.2276; found, 352.2278; HPLC: method A, 12.08 minutes (97.3%); method B, 16.36 minutes (98.9%); Anal. Calcd for C₂₃H₂₉NO₂•0.75H₂O: C, 75.67; H, 8.43; N, 3.84. Found: C, 75.40; H, 7.93; N, 3.78.

EXAMPLE 18


trans-*N*-[4-(4-Hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)carbamic acid methyl ester

To a stirred solution of *trans*-4-[4-(3-phenylpropylamino) cyclohexyl]-phenol (0.40 g, 1.3 mmol) in a mixture of 2 N NaOH (5 mL) and THF (5 mL) was added methyl chloroformate (0.12 mL, 1.6 mmol). The reaction mixture was stirred at room temperature for 2 hours. Methyl chloroformate (0.05 mL,

0.65 mmol) was added and stirring continued for another 2 hours. The mixture was diluted with EtOAc (50 mL), washed with H₂O, dried (Na₂SO₄), filtered and concentrated under reduced pressure. Purification by flash chromatography (silica, 97:3 MeOH/CH₂Cl₂) gave *trans*-*N*-[4-(4-hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)carbamic acid methyl ester, as an off-white solid (0.068 g, 14%): mp 128-133°C; IR (KBr): 3403, 2923, 1673, 1518 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 7.31-7.15 (m, 5H), 7.01 (d, *J* = 8 Hz, 2H), 6.68 (d, *J* = 8 Hz, 2H), 3.91-3.78 (m, 1H), 3.67 (s, 3H), 3.25-3.13 (m, 2H), 2.61 (t, *J* = 8 Hz, 2H), 2.40-2.29 (m, 1H), 1.95-1.45 (m, 10H); CI-MS (methane) (*m/z*): 368 [M + 1]⁺; HRMS-API (*m/z*): [M + 1]⁺ Calcd for C₂₃H₂₉NO₃, 368.2225; found, 368.2227; HPLC: method A, 13.78 minutes (85.2%).

EXAMPLE 19

trans-*N*-benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]carbamic acid methyl ester




Following the procedure described in Example 18, *trans*-*N*-benzyl-*N*-[4-(4-hydroxyphenyl)cyclohexyl]carbamic acid methyl ester was prepared from *trans*-4-(4-benzylamino-cyclohexyl)phenol and methyl chloroformate yield (175 mg, 29%): mp 61-66°C; IR (KBr): 3368, 2930, 1670, 1614 cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ 9.08 (s, 1H), 7.34-7.17 (m, 5H), 6.97 (d, *J* = 9 Hz, 2H), 6.64 (d, *J* = 9 Hz, 2H), 4.45 (s, 2 H), 3.62 (m, 1H), 3.32 (s, 3H), 2.51 (m, 1H), 1.75-1.41 (m, 8H); CI-MS (methane) (*m/z*): 340 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₁H₂₅NO₃, 340.1912; found: 340.1908; HPLC: method A, 10.30 minutes (98.6%); method B, 16.58 minutes (99.6%); Anal. Calcd for C₂₁H₂₅NO₃•0.125H₂O: C, 73.82; H, 7.45; N, 4.10. Found: C, 73.72; H, 7.58; N, 3.98.

44

EXAMPLE 20

4-{4-[Methyl(3-phenylpropyl)amino]cyclohexyl}phenol




To an ice-cold, stirred solution of *trans*-*N*-[4-(4-hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)carbamic acid methyl ester (0.30 g, 0.82 mmol) in anhydrous THF (20 mL), under a N₂ atmosphere, was added LiAlH₄ (95% powder, 0.034 g, 0.89 mmol). The reaction mixture was stirred at room temperature for 6 hours. LAH (95% powder, 0.07 mg, 1.8 mmol) was added, and stirring was continued for 14 hours. The reaction mixture was then quenched by the slow addition of H₂O (2 mL). The mixture was partitioned between EtOAc and H₂O, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica, 9:1 MeOH:CH₂Cl₂) gave *trans*-4-{4-[methyl(3-phenylpropyl)amino]cyclohexyl}phenol (0.19 g, 70%) as an off-white solid: IR (thin film): 2931, 1613, 1515 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 7.30-7.11 (m, 5H), 7.00 (d, *J* = 8 Hz, 2H), 6.67 (d, *J* = 8 Hz, 2H), 2.69-2.49 (m, 5H), 2.41-2.31 (m, 1H), 2.30 (s, 3H), 2.00-1.78 (m, 6H), 1.55-1.34 (m, 4H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₂H₂₉NO, 324.2327; found, 324.2333; HPLC: method A, 7.82 minutes (99.8%); method B, 13.89 minutes (99.7%); Anal. Calcd for C₂₂H₂₉NO•0.25 H₂O: C, 80.57; H, 9.07; N, 4.27. Found: C, 80.51; H, 8.83; N, 4.27.

EXAMPLE 21

trans-*N*-[4-(4-Hydroxyphenyl)cyclohexyl]-3-phenylpropionamide

45



An ice-cold solution of hydrocinnamic acid (0.20 g, 1.3 mmol), Et₃N (0.20 mL, 1.4 mmol), and ethyl chloroformate (0.13 mL, 1.3 mmol) in THF (20 mL) was stirred under a N₂ atmosphere for 5 minutes. *Trans*-4-(4-

5 hydroxyphenyl)cyclohexylamine **5** (0.25 g, 1.3 mmol) was added, and the mixture was stirred at room temperature for 2.5 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. Purification by flash chromatography (silica, 90:2:1 CH₂Cl₂:EtOAc:MeOH to 9:1 CH₂Cl₂:MeOH)

gave IUPAC: *trans*-N-[4-(4-Hydroxyphenyl)cyclohexyl]-3-phenylpropionamide (140 mg, 32%) as an off-white solid: mp 201-206°C; IR (KBr): 3298, 2931, 1638,


10 1514 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 7.30-7.13 (m, 5H), 7.01 (d, *J* = 9 Hz, 2H), 6.68 (d, *J* = 9 Hz, 2H), 3.71-3.49 (m, 1H), 2.90 (t, *J* = 7 Hz, 2H), 2.44 (t, *J* = 7 Hz, 2H), 2.41-2.31 (m, 1H), 1.95-1.78 (m, 4H), 1.58-1.42 (m, 2H), 1.35-

1.19 (m, 2H); CI-MS (methane) (*m/z*): 324 [M + H]⁺; HRMS-API (*m/z*):

15 [M + H]⁺ Calcd for C₂₁H₂₅NO₂, 324.1963; found, 324.1962; HPLC: method A, 10.88 minutes (97.5%); method B, 13.57 minutes (99.4%); Anal. Calcd for C₂₁H₂₅NO₂•0.25H₂O: C, 76.91; H, 7.84; N, 4.27. Found: C, 77.04; H, 7.84; N, 3.88.

EXAMPLE 22

20 *trans*-N-[4-(4-Hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxy-propionamide




Step 1: 2-Methyl-2-phenoxypropionic acid **6** was prepared following the procedure of Corey et al., *J. Am. Chem. Soc.* 1969;91:4782. To an ice-cold, stirred suspension of powdered NaOH (3.2 g, 80 mmol) in acetone (40 mL) was added phenol (1.88 g, 20 mmol) followed by 1,1,1-trichloro-2-methyl-2-propanol hydrate (7.82 g, 40 mmol). The mixture was stirred at 0°C for 2 hours and then at room temperature for 2 hours. The mixture was diluted with H₂O, acidified with 2N HCl, and extracted with EtOAc. The organic layer was washed with 2 N HCl, then extracted with saturated NaHCO₃ (2×). The aqueous extracts were combined, washed once with EtOAc, acidified with 2N HCl, then extracted with EtOAc (2×). The combined organic layers were washed once with saturated NaCl, dried (MgSO₄), and concentrated under reduced pressure. Purification by flash chromatography gave **6** (1.36 g, 38%): ¹H NMR (300 MHz, CDCl₃) δ 7.28 (t, *J* = 8 Hz, 2H), 7.08 (t, *J* = 8 Hz, 1H), 6.96 (d, *J* = 8 Hz, 2H), 1.52 (s, 6H).

Step 2: *trans*-*N*-[4-(4-Hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxypropionamide: Reaction of *trans*-1-amino-4-(4-hydroxyphenyl)-cyclohexane **5** with **6**, following the procedure described in Example 5, gave *trans*-*N*-[4-(4-hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxypropionamide (0.40 g, 86%): mp 114-117°C; IR (KBr): 3355, 2930, 1654, 1515 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 7.30-7.22 (m, 2H), 7.05-6.80 (m, 3H), 6.90 (br d, *J* = 8 Hz, 2H), 6.68 (br d, *J* = 8 Hz, 2H), 3.83-3.71 (m, 1H), 2.48-2.32 (m, 1H), 2.0-1.8 (m, 4H), 1.5 (s, 6H), 1.61-1.30 (m, 4H); CI-MS (methane) (*m/z*): 354 [M+1]⁺; HRMS-API (*m/z*): [M + 1]⁺ Calcd for C₂₂H₂₇NO₃, 354.2069; found, 354.2058; HPLC: method A, 12.22 minutes (95.1%); method B, 8.70 minutes (96.9%); Anal. Calcd for C₂₂H₂₇NO₃•0.25H₂O: C, 73.82; H, 7.74; N, 3.91. Found: C, 73.46; H, 7.76; N, 3.80.

EXAMPLE 23


trans-4-[4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol



Step 1: 1-phenyl-2-propyn-1-yl methanesulfonate. To an ice-cold solution of 1-phenyl-2-propyn-1-ol (0.50 g, 3.8 mmol) in THF (15 mL), under a N₂ atmosphere, was added Et₃N (0.78 mL, 5.7 mmol), followed by methanesulfonyl chloride (0.35 mL, 4.5 mmol). After 15 minutes, the reaction mixture was diluted with EtOAc (50 mL), washed with 2N HCl, H₂O, saturated NaHCO₃, and saturated NaCl. The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure to give the mesylate 7 (0.79 mg, 100%), which was used without further purification.

Step 2: *trans*-4-[4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol. A mixture of *trans*-4-(4-hydroxyphenyl)cyclohexylamine 5 (0.35 g, 1.8 mmol) and mesylate 7 (0.32 g, 1.5 mmol) in THF (15 mL) was refluxed under N₂ for 17 hours. The reaction mixture was diluted with EtOAc (40 mL) and washed with H₂O, then saturated NaCl, dried (Na₂SO₄), filtered, and concentrated under reduced pressure. Purification by flash chromatography (silica, 99:1 CHCl₃:MeOH to 97:3 CHCl₃:MeOH) and conversion to the maleate salt gave *trans*-4-[4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol (160 mg, 26%) as a white solid: mp 171-179°C; IR (KBr): 2938, 1700, 1516 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 7.52-7.35 (m, 5H), 7.04 (d, *J* = 8 Hz, 2H), 6.69 (d, *J* = 8 Hz, 2H), 6.25 (s, 2H), 4.21 (s, 2H), 3.45-3.35 (obs m, 1H), 2.52-2.42 (m, 1H), 2.31-2.20 (m, 2H), 2.05-1.60 (m, 2H), 1.67-1.48 (m, 4H); CI-MS (methane) (*m/z*): 306 [M + H]⁺; HPLC: method A, 7.63 minutes (97.9%); method B, 14.01 minutes (97.6%); Anal. Calcd for C₂₁H₂₃NO•C₄H₄O₄: C, 71.24; H, 6.46; N, 3.32. Found: C, 71.21; H, 6.51; N, 3.22.

EXAMPLE 24

trans-4-[4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol


Step 1: A solution of phenylsulfanylacetic acid (0.22 g, 1.3 mmol), amine
 5 (0.25 g, 1.3 mmol), EDC (0.31 g, 1.6 mmol), and HOBT (0.18 g, 1.3 mmol) in
 DMF (5 mL) was stirred under an N₂ atmosphere overnight. The reaction mixture
 was concentrated under reduced pressure. Purification by flash chromatography
 (silica, 9:1 CH₂Cl₂:MeOH) gave the desired amide (0.27 g, 61%): CI-MS
 (methane) m/z = 342 [M + H]⁺.

Step 2: To a magnetically stirred suspension of the amide (0.27 g,
 0.78 mmol) in THF (5 mL), under an N₂ atmosphere, was added DIBAL-H
 (1.6 mL of a 1 M solution in THF, 1.6 mmol). The reaction mixture was stirred at
 room temperature for 1 hour and then heated to reflux. After 1 hour at reflux,
 additional DIBAL-H (1.6 mL of a 1 M solution in THF, 1.6 mL, 1.6 mmol) was
 added and the reaction mixture was stirred at reflux overnight. Additional
 DIBAL-H (0.8 mL of a 1 M solution in THF, 0.8 mmol) was added, and after
 4 hours, the reaction mixture was cooled to room temperature. The reaction
 mixture was quenched by the slow addition of MeOH (50 mL), and the resultant
 mixture was heated under reflux for 15 minutes. The remaining solid was
 removed by filtration, and the filtrate was concentrated under reduced pressure.
 Purification by flash chromatography (silica, 95:5 CH₂Cl₂:MeOH) gave *trans*-4-
 [4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol (0.11 g, 41%) as a white solid:
 mp 131-136°C, IR (KBr): 2921, 1611, 1592, 1514 cm⁻¹; ¹H NMR (300 MHz,
 CD₃OD) δ 7.42-7.19 (m, 5H), 7.00 (d, J = 9 Hz, 2H), 6.67 (d, J = 9 Hz, 2H),

3.08 (t, $J = 7$ Hz, 2H), 2.83 (t, $J = 7$ Hz, 2H) 2.51 (tt, $J = 15, 3$ Hz, 1H), 2.39 (tt, $J = 15, 3$ Hz, 1H), 1.98 (br d, $J = 12$ Hz, 2H), 1.83 (br d, $J = 12$ Hz, 2H), 1.50 (dddd, $J = 15, 15, 15, 3$, 2H), 1.22 (dddd, $J = 15, 15, 15, 3$ Hz, 2H): CI-MS (methane) (m/z): 328 $[M + H]^+$; HRMS-API (m/z): $[M + H]^+$ Calcd for $C_{20}H_{25}NOS$, 328.1735; found, 328.1746; HPLC: method A, 7.69 minutes (97.9%); method B, 14.13 minutes (99.7%); Anal. Calcd for $C_{20}H_{25}NOS$: C, 72.36; H, 7.74; N, 4.22. Found: C, 72.70; H, 7.73; N, 4.21.

EXAMPLE 25

trans-4-[4-(2-phenylaminoethylamino)cyclohexyl]phenol




To a stirred solution of 4-(4-hydroxyphenyl)cyclohexanone (1.0 g, 5.3 mmol) in a mixture of 2-propanol (40 mL) and THF (20 mL) was added *N*-phenylethylenediamine (0.72 g, 5.3 mmol) and 3Å molecular sieves. After 3 hours, sodium borohydride (0.27 g, 7.3 mmol) was added, and the reaction mixture was stirred overnight. The reaction mixture was quenched with MeOH, filtered through celite, and the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography (silica, 95:5 CH_2Cl_2 :MeOH) and converted to a maleate salt. Recrystallization from MeOH/Et₂O gave *trans*-4-[4-(2-phenylamino-ethylamino)cyclohexyl]phenol (0.31 g, 14%), as yellow solid: mp 180-184 °C; IR (KBr): 3368, 2945, 2863, 1516 cm^{-1} ; 1H NMR (500 MHz, DMSO- d_6) δ 9.14 (s, 1H), 8.40 (br s, 2H), 7.15-7.00 (m, 4H), 6.70-6.55 (m, 5H), 6.02 (s, 2H), 5.65 (br s, 1H), 3.40-3.25 (m, 2H), 3.20-3.10 (m, 3H), 2.45-2.40 (m, 1H), 2.20-2.10 (m, 2H), 1.90-1.80 (m, 2H), 1.50-1.35 (m, 4H); API-MS (m/z): 311 $[M + H]^+$; HPLC: method A, 7.38 minutes (99.1%); method B, 13.29 minutes

(99.1%); Anal. Calcd for $C_{20}H_{26}N_2O \cdot C_4H_4O_4$: C, 67.59; H, 7.09; N, 6.57.

Found: C, 67.38; H, 7.01; N 6.55.

EXAMPLE 26

trans-4-{4-[*N*-ethyl-*N*-(3-phenylpropyl)amino]cyclohexyl}phenol.




To a stirred solution of *trans*-*N*-[4-(4-hydroxyphenyl)cyclohexyl]-*N*-(3-phenylpropyl)acetamide (282 mg, 0.80 mmol) in anhydrous THF (5 mL) was added $LiAlH_4$ (1.2 mL of a 1 M solution in Et_2O , 1.2 mmol). After 18 hours, the reaction was quenched by addition of a mixture of H_2O (2 mL), 2N NaOH (4 mL), and saturated NaCl (2 mL). The resulting mixture was diluted with Et_2O (100 mL) and the resulting mixture was filtered. The filtrate was dried (Na_2SO_4) and concentrated under reduced pressure. Purification by flash chromatography (90:9:1 CH_2Cl_2 :MeOH: NH_4OH) gave *trans*-4-{4-[*N*-ethyl-*N*-(3-phenylpropyl)amino]cyclohexyl}phenol (130 mg, 48%) as a white solid: mp 192-194°C; IR (KBr): 3197, 2939, 1614, 1516 cm^{-1} ; 1H NMR (500 MHz, $DMSO-d_6$) δ 9.16 (br s, 1H), 7.35-7.23 (m, 5H), 7.02 (d, $J = 8$ Hz, 2H), 6.70 (d, $J = 8$ Hz, 2H), 3.35-3.12 (m, 5H), 2.68 (q, $J = 5$, 2 Hz, 2H), 2.42 (tt, $J = 9$, 2 Hz, 1H), 2.12 (br d, $J = 9$ Hz, 2H), 2.10 (m, 2H), 1.87 (br d, $J = 9$ Hz, 2H), 1.63 (dddd, $J = 9$, 9, 9, 2 Hz, 2H), 1.53 (dddd, $J = 9$, 9, 9, 2 Hz, 2H), 1.27 (t, $J = 5$ Hz, 3H); CI-MS (methane) (m/z): 338 $[M + H]^+$; HPLC: method A, 8.80 minutes (97.8%); method B, 10.66 minutes (99.9%); Anal. Calcd for $C_{23}H_{31}NO \cdot HCl \cdot 0.125H_2O$: C, 73.43; H, 8.64; N, 3.72. Found: C, 73.36; H, 8.75; N, 3.56.

EXAMPLE 27

trans-4-{4-[*N*-isopropyl-*N*-(3-phenylpropyl)amino]cyclohexyl}phenol


51



To a stirred solution of *trans*-4-[4-(3-phenylpropylamino) cyclohexyl]-phenol and acetone (2 mL) in a 2:1 mixture of THF:MeOH (10 mL) was added sodium cyanoborohydride (153 mg, 2.42 mmol). The reaction mixture was heated to 60°C and the acidity was maintained by the addition of acetic acid. The mixture was stirred overnight, quenched with 2N NaOH and concentrated under reduced pressure. Purification by flash chromatography (90:9:1 CH₂Cl₂:MeOH:NH₄OH) gave *trans*-4-{4-[*N*-isopropyl-*N*-(3-phenylpropyl) amino]cyclohexyl}phenol (130 mg, 48%), as a white solid: mp 146-154°C; IR (KBr): 3198, 2941, 1613 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ or s δ 7.32-7.21 (m, 5H), 6.98 (d, *J* = 8 Hz, 2H), 6.66 (d, *J* = 8 Hz, 2H), 3.67 (m, 1H), 3.28 (m, 2H), 3.10 (m, 2H), 2.66 (m, 2H), 2.48 (m, 1H), 2.04 (m, 1H), 2.02 (m, 2H), 1.84 (m, 2H), 1.83 (m, 2H), 1.49 (m, 2H), 1.24 (d, *J* = 8 Hz, 3H), 1.19 (d, *J* = 8 Hz, 3H); CI-MS (methane) (*m/z*): 352 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₄H₃₃NO, 352.2640; found, 352.2637; HPLC: method A, 6.37 minutes (95.3%); method B, 10.85 minutes (100%); Anal. Calcd for C₂₄H₃₃NO•HCl•0.5 NaCl: C, 69.09; H, 8.21; N, 3.36. Found: C, 69.33; H, 8.32; N, 3.22.

EXAMPLE 28

trans-4-{4-[3-(4-methoxyphenyl)propylamino]cyclohexyl}phenol




To a stirred solution of amine 5 (0.30 g, 1.6 mmol) and 3-(4-methoxyphenyl)propionaldehyde (0.26 g, 1.6 mmol) in a mixture of MeOH (5 mL) and 1,2-dichloroethane (10 mL) was added sodium triacetoxymethylborohydride (0.47 g, 2.2 mmol). After 4 hours, the solvents were removed under reduced pressure. The product was partitioned between EtOAc and H₂O and the mixture shaken until most of the solids dissolved. The organic solution was washed with

saturated NaHCO_3 , filtered, then washed with a mixture of 1N HCl containing a little saturated NaCl. A precipitate formed which was collected by filtration. Recrystallization from MeOH gave the HCl salt, *trans*-4-{4-[3-(4-methoxyphenyl)propylamino]cyclohexyl}phenol (0.22 g, 62%), as a white solid: mp 235-241°C; IR (KBr): 1514, 1249, 1033 cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.15 (s, 1H), 8.79 (br s, 2H), 7.16, 7.00, 6.88, and 6.67 (all d, $J = 8.4$ Hz, 2H), 3.74 (s, 3H), 3.03 (m, 1H), 2.88 (m, 2H), 2.60 (t, $J = 7.6$ Hz, 2H), 2.37 (m, 1H), 2.12 (br d, $J = 12.1$ Hz, 2H), 2.12 (tt, $J = 7.6, 7.6$ Hz, 2H), 1.83 (br d, $J = 12.3$ Hz, 2H), 1.53-1.35 (m, 4H); CI-MS (methane) (m/z): 340 $[\text{M} + \text{H}]^+$; HRMS-API (m/z): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{29}\text{NO}_2$, 340.2276; found, 340.2273; HPLC: method A, 7.76 minutes (99.4%); method B, 14.04 minutes (99.9%); Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{NO}_2 \cdot \text{HCl} \cdot 0.125 \text{H}_2\text{O}$: C, 69.87; H, 8.06; N, 3.70. Found: C, 69.77; H, 7.71; N, 3.60.

EXAMPLE 29

4-{4-[benzyl(3-phenylpropyl)amino]cyclohexyl}phenol



Step 1: A mixture of **1** (10 g, 0.05 mol) and benzylamine (5.75 mL, 0.05 mol) in toluene (150 mL) was heated under Dean-Stark conditions for 3 hours. The solution was cooled to room temperature and then concentrated under reduced pressure. 2-PrOH (100 mL) was added, and the mixture was heated under reflux until all of the solid dissolved. The solution was cooled in an ice bath and sodium borohydride (3 g, 0.079 mol) was added. The mixture was stirred at room temperature for 1 hour. Methanol (100 mL) was added, and stirring was continued for 1 hour. The mixture was acidified with 2N HCl and then shaken between water and Et₂O. The *trans*-isomer **9** precipitated from solution, yield (9.35 g, 59%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.26 (br s, 2H), 9.14 (br s, 1H), 7.60 (dd, *J* = 8, 2 Hz, 2H), 7.40-7.48 (m, 3H), 7.01 (d, *J* = 9 Hz, 2H), 6.68 (d, *J* = 9 Hz, 2H), 4.17 (t, *J* = 6 Hz, 2H), 3.05 (m, 1H), 2.49 (tt, *J* = 12, 4 Hz, 1H), 2.25 (br d, *J* = 11 Hz, 2H) 1.85 (br d, *J* = 12 Hz, 2H), 1.61 (dddd, *J* = 12, 12, 12, 3 Hz, 2H), 1.42 (dddd, *J* = 12, 12, 12, 3 Hz, 2H).


Step 2: To a solution of hydrocinnamic acid (1.0 g, 6.6 mmol) in CH₂Cl₂ (20 mL) was added DMF (5 drops) and oxalyl chloride (0.7 mL, 8.0 mmol). After stirring for 30 minutes, DMF (10 mL) was added slowly. When the vigorous evolution of gas subsided, the CH₂Cl₂ was removed under reduced pressure. Compound **9** (1.0 g, 3.2 mmol) and triethylamine (1.7 mL, 12.2 mmol) were added, and the mixture was heated to 80°C. After 1 hour, triethylamine (1.0 mL, 7.2 mmol) was added, and heating was continued for 1 hour. The reaction mixture was cooled to room temperature and partitioned between EtOAc and 2N HCl. The organic layer was washed with 2N HCl, water, saturated NaHCO₃, and saturated NaCl, dried (MgSO₄), and concentrated under reduced pressure. The residue was taken up in MeOH (20 mL), K₂CO₃ (0.5 g) added, and the mixture stirred at room temperature overnight. The reaction mixture was diluted with water and EtOAc, and then acidified with 2N HCl. The organic layer was washed with 2N HCl, sat. NaHCO₃, and sat. NaCl, dried (MgSO₄), and concentrated under reduced pressure. Purification by flash chromatography (4:1 to 3:1 to 2:1 hexanes:EtOAc) gave **10** (0.86 g, 66%) as a mixture of isomers: ¹H NMR (300 MHz, CDCl₃) δ 6.70-7.40 (m, 14H), 4.63 (m, 1H), 4.62 and 4.40 (both

s, 2H), 3.73 (m, 1H), 3.09 and 2.98 (both t, $J = 7$ Hz, 2H), 2.70 and 2.55 (both t, $J = 7$ Hz, 2H), 2.33 (m, 1H), 1.30-1.95 (m, 8H).

Step 3: A solution of amide **10** (0.86 g, 2 mmol) and $\text{BH}_3 \cdot \text{SMe}_2$ (2 mL of a 2 M solution in THF, 4 mmol) in THF (20 mL) was stirred at room temperature overnight and then heated under reflux for 15 min. After cooling to room temperature, MeOH (20 mL) was added, and the mixture was concentrated under reduced pressure. MeOH (20 mL) was added, followed by concentrated HCl (0.5 mL), and the mixture was concentrated under reduced pressure. The residue was twice taken up in MeOH (20 mL) and re-concentrated. The product was re-crystallized from MeOH (5 mL). The product was dissolved in a hot MeOH: CHCl_3 mixture and the resultant solution neutralized with dilute NaHCO_3 . The free amine was extracted into CHCl_3 . The organic solution was dried (MgSO_4) and concentrated under reduced pressure. Purification by flash chromatography (silica, eluent CHCl_3 to 98:2 CHCl_3 :MeOH), followed by conversion to the HCl salt, gave 4-{4-[benzyl-(3-phenylpropyl)amino]-cyclohexyl}phenol (0.62 g, 68%), as a white solid: mp 259-264°C; IR (KBr): 1613, 1515, 1225 cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.58 (br s, 1H), 9.12 (br s, 1H), 7.57 (dd, $J = 6, 2$ Hz, 1H), 7.46 (d, $J = 2$ Hz, 1H), 7.45 (d, $J = 6$, 1H), 7.28 (t, $J = 7$ Hz, 2H), 7.19 (t, $J = 7$ Hz, 1H), 7.16 (d, $J = 7$ Hz, 2H), 7.00 (d, $J = 9$ Hz, 2H), 6.68 (d, $J = 8$ Hz, 2H), 4.46 (dd, $J = 13, 4$ Hz, 1H), 4.24 (dd, $J = 13, 7$ Hz, 1H), 3.35-3.40 (m, 1H), 3.12-3.20 (m, 1H), 2.99 (br t, $J = 11$ Hz, 1H), 2.40-2.60 (m, 3H), 2.17 (d, $J = 11$ Hz, 2H), 1.96-2.06 (m, 1H), 1.88 (d, $J = 11$ Hz, 2H), 1.68-1.86 (m, 3H), 1.42-1.52 (m, 2H); CI-MS (methane) (m/z): 400 $[\text{M} + \text{H}]^+$; HPLC: method A, 7.52 min (96.5%); method B, 11.25 min (>99%); Anal. Calcd for $\text{C}_{28}\text{H}_{33}\text{NO} \cdot \text{HCl}$: C, 77.13; H, 7.86; N, 3.21. Found: C, 76.78; H, 8.09; N, 3.14.

EXAMPLE 30


4-{4-[methyl(2-phenoxyethyl)amino]cyclohexyl}phenol



To a stirred solution of 4-[4-(2-phenoxyethylamino)cyclohexyl]phenol (0.35 g, 1.13 mmol) in a mixture of MeOH (10 mL), water (1 mL) and CH₂Cl₂ (5 mL) was added *p*-formaldehyde (0.17 g, 5.62 mmol). The reaction mixture was stirred for 2 hours, sodium triacetoxyborohydride (0.33 g, 1.58 mmol) was added and stirring was continued overnight. Solid NaOH was added, until the solution turned clear. Silica gel was added, and the solvents were removed under reduced pressure. Purification by flash chromatography (10:1 CH₃Cl:MeOH) gave 4-{4-[methyl(2-phenoxyethyl)amino] cyclohexyl}-phenol (264 mg, 72%) as a white solid: mp 216-220°C; IR (KBr): 3149, 2936, 1599 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.14 (br s, 1H), 7.34 (dd, *J* = 9, 9 Hz, 2H), 7.00 (d, *J* = 9 Hz, 5H), 6.68 (d, *J* = 9 Hz, 2H), 4.42 (br s, 2H), 3.61-3.33 (m, 3H), 2.82 (s, 3H), 2.92 (t, *J* = 5 Hz, 2H), 2.49 (tt, *J* = 10, 2 Hz, 1H), 2.19 (dd, *J* = 10, 2 Hz), 1.88 (br d, *J* = 10 Hz, 2H), 1.74 (dddd, *J* = 10, 10, 10, 2 Hz, 2H), 1.47 (dddd, *J* = 10, 10, 10, 2 Hz, 2H); CI-MS (methane) (*m/z*): 326 [M + H]⁺; HPLC: method A, 5.64 min (95.3%); method B, 9.63 min (99.2%); Anal. Calcd for C₂₄H₃₃NO•HCl: C, 69.69; H, 7.80; N, 3.87. Found: C, 69.44; H, 7.81; N, 3.80.

EXAMPLE 31

2-aminomethyl-4-{4-[ethyl(3-phenylpropyl)amino]cyclohexyl}phenol



(Stokker G.E., Deana A.A., deSolms S.J., Schultz E.M., Smith R.L., Cragoe E.J.Jr., *J. Med. Chem.*, 1980;23:1414).

A mixture of HOAc and H₂SO₄ (1 mL, 9:1, v:v) was cooled to 10°C. 4-{4-[ethyl(3-phenylpropyl)amino]cyclohexyl}phenol (200 mg, 0.53 mmol) and 2-chloro-N-(hydroxymethyl)acetamide (66 mg, 0.53 mmol) were added portionwise.

The reaction mixture was warmed to room temperature and stirred for 16 hours. The mixture was poured onto ice (1 g) and water (10 mL) was added. After concentration under reduced pressure, a mixture of EtOH and HCl (6.5 mL, 10:3, v:v) was added, and the mixture was heated under reflux for 1.5 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. Purification by flash chromatography (silica, 90:10:0.5 CH₂Cl₂:MeOH:NH₄OH), followed by formation of the HCl salt, gave 2-aminomethyl-4-{4-[ethyl(3-phenylpropyl)amino]cyclohexyl}phenol (65 mg, 28%), as a yellow solid: mp 168-173°C; IR (KBr): 2940, 1510, 1453 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.16 (br s, 1H), 9.96 (s, 1H), 8.1 (br s, 2H), 7.35-7.17 (m, 6H), 7.06 (dd, *J* = 8 Hz, 1H), 6.85 (d, *J* = 8 Hz, 1H), 3.90 (br d, *J* = 5 Hz, 2H), 3.45-2.98 (m, 4H), 2.71-2.65 (m, 2H), 2.52-2.39 (m, 2H), 2.19-2.10 (m, 2H), 2.10-2.05 (m, 2H), 1.90-1.83 (m, 2H), 1.70-1.49 (m, 4H), 1.27 (t, *J* = 7 Hz, 3H) API-MS (methane) (*m/z*): 367 [M + H]⁺; HRMS-API (*m/z*): [M + H]⁺ Calcd for C₂₄H₃₄N₂O, 367.2749; found, 367.2741; Anal. Calcd for C₂₄H₃₄N₂O•2HCl•H₂O: C, 64.93; H, 8.29; N, 6.31. Found: C, 64.90; H, 8.53; N, 6.09.

Electrophysiological Assays at NMDA receptor subunits

Preparation of RNA. cDNA clones encoding the NR1A, NR2A, NR2B, and NR2C rat NMDA receptor subtypes were used (see Moriyoshi et al., *Nature (Lond.)*, 1991;354:31-37); Kutsuwada et al., *Nature (Lond.)*, 1992;358: 36-41; Monyer et al., *Science (Washington, D.C.)*, 1992;256:1217-1221; Ikeda et al., *FEBS Lett.*, 1992;313:34-38; Ishii et al., *J. Biol. Chem.* 1993;268:2836-2843 for details of these clones or their mouse homologs). The clones were transformed into appropriate host bacteria and plasmid preparations were made with conventional DNA purification techniques. A sample of each clone was linearized by restriction enzyme digestion of cRNA was synthesized with T3 RNA polymerase. The cRNA was diluted to 400 ng/μL and stored in 1 μL aliquots at -80°C until injection.

The *Xenopus* oocyte expression system. Mature female *Xenopus laevis* were anaesthetized (20-40 minutes) using 0.15% 3-aminobenzoic acid ethyl ester

(MS-222), and 2 to 4 ovarian lobes were surgically removed. Oocytes at developmental stages IV-VI (Dumont J.N., *J. Morphol.*, 1972;136:153-180) were dissected from the ovary still surrounded by enveloping ovarian tissues. Follicle-enclosed oocytes were micro-injected with 1:1 mixtures of NR1A:NR2A, 2B or 2C; injecting 1 to 10 ng of RNA encoding each receptor subunit. NR1A encoding RNA was injected alone at ~20 ng. Oocytes were stored in Barth's medium containing (in mM): NaCl, 88; KCl, 1; CaCl₂, 0.41; Ca (NO₃)₂, 0.33; MgSO₄, 0.82; NaHCO₃, 2.4; HEPES 5, pH 7.4, with 0.11 mg/mL gentamicin sulphate. While oocytes were still surrounded by enveloping ovarian tissues, the Barth's medium was supplemented with 0.1% bovine serum. Oocytes were defolliculated 1 to 2 days following injections by treatment with collagenase (0.5 mg/mL Sigma Type I for 0.5-1 hour) - (Miledi and Woodward, *J. Physiol. (Lond.)*, 1989;416:601-621) and subsequently stored in serum-free medium.

Electrical recordings were made using a conventional two-electrode voltage clamp (Dagan TEV-200) over periods ranging between 3 to 21 days following injection (Woodward et al., *Mol. Pharmacol.*, 1992;41:89-103). Oocytes were placed in a 0.1 mL recording chamber continuously perfused (5-15 mL min⁻¹) with frog Ringer's solution containing (in mM): NaCl, 115; KCL, 2; BaCl₂, 1.8; HEPES, 5; pH 7.4. Drugs were applied by bath perfusion.

Using oocytes expressing different subunit combinations of NMDA receptor, NMDA currents were activated by co-application of glutamate (100 µM) and glycine (1-100 µM). Inhibitory potency of the novel antagonists was assessed on responses elicited by fixed concentrations of glutamate and glycine, by measuring reductions in current induced by progressively increasing concentrations of antagonist.

Concentration-inhibition curves were fit with Equation 1.

$$I/I_{\text{control}} = 1/(1 + ([\text{antagonist}]/10^{-\text{pIC}_{50}})^n) \quad \text{Eq.1}$$

In which I_{control} is the current evoked by agonists alone, $\text{pIC}_{50} = -\log \text{IC}_{50}$, IC_{50} is the concentration of antagonist that produced half maximal inhibition, and

n is the slope factor (De Lean et al., *Am. J. Physiol.*, 1978;235:E97-102). For incomplete curves analysis by fitting was unreliable and IC₅₀ values were calculated by simple regression over linear portions of the curves (Origin: Microcal Software).

5 The electrophysiological assay results are set forth in Tables 1-4.

6-OHDA-lesioned rat assay:

6-Hydroxydopamine-lesioned rats were used (see Ungerstedt U., Arbuthnott G.W., Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. *Brain Res.*,
10 1971;24(3):485-93). Adult male Sprague-Dawley rats were anesthetized with chloral hydrate and unilateral lesions of the nigrostriatal dopamine system were accomplished by infusion of 8 µg of 6-hydroxydopamine HBr (6-OHDA) into the right medial forebrain bundle. Rats were pretreated 30 minutes before surgery with desipramine HCl 25 mg/kg intraperitoneally (IP) to protect noradrenergic
15 neurons, and pargyline 25 mg/kg IP to potentiate the effects of 6-OHDA. A minimum of 3 weeks after surgery, the rotational behavior induced by apomorphine HCl 50 µg/kg subcutaneously (SC) was assessed. Only rats demonstrating more than 100 contraversive turns/hour to apomorphine were used for the present experiments.

20 Rotational behavior was measured using an automatic rotometer system (Rotorat Rotational Activity System, MED Associates, Georgia, VT). Anti-parkinsonian activity was assessed as the ability of the compound to potentiate the contraversive rotation induced by L-DOPA methyl ester, 10 mg/kg SC, over a 6-hour period. Experiments were conducted using a crossover paradigm where
25 each rat received either a vehicle plus L-DOPA, or the test compound plus L-DOPA, in randomized order. Rats were tested at 7-day intervals. In experiments in which the compound was tested orally, rats were food deprived for 16 hours. Statistical analysis between treatment groups were performed using a paired t-test. The results were reported in Table 1 as the minimum effective dose (MED) of
30 compound required to produce a statistically-significant increase in total contraversive rotations compared to rats receiving L-DOPA only.

59

Table 1


			
Example No.	N	<i>cis/trans</i>	NR1a/NR2B Oocyte IC ₅₀ (μM)
2b	3	<i>trans</i>	0.034
1b	4	<i>trans</i>	0.035
2a	3	<i>cis</i>	0.60
9	5	<i>trans</i>	0.35
3b	2	<i>trans</i>	0.45
3a	2	<i>cis</i>	0.83
1a	4	<i>cis</i>	0.90
4b	1	<i>trans</i>	43.00
4a	1	<i>cis</i>	70.00

Table 2










				
Example No.	Z	R	<i>cis/trans</i>	IC ₅₀ (μM)
11b		H	<i>trans</i>	0.02
23		H	<i>trans</i>	0.05
21		H	<i>trans</i>	0.07
6b		H	<i>trans</i>	0.10
6a		H	<i>cis</i>	0.60
11a		H	<i>cis</i>	2.0
13		H	<i>trans</i>	16
22		H	<i>trans</i>	301

Table 2 (Continued)










				
Example No.	Z	R	cis/trans	IC ₅₀ (μM)
24		H	<i>trans</i>	0.04
6c		H	<i>trans</i>	0.06
6d		H	<i>trans</i>	0.07
25		H	<i>trans</i>	0.05
10b		H	<i>trans</i>	5.0
10a		H	<i>cis</i>	29
16	CH ₂	C(O)CH ₃	<i>trans</i>	200
18		CH ₃	<i>trans</i>	0.05
17	(CH ₂) ₃	C(O)CH ₃	<i>trans</i>	4.4
19	CH ₂	C(O)CH ₃	<i>trans</i>	240

Table 3

				
Example No.	N	Ar	cis/trans	NR1a/NR2B Oocyte IC ₅₀ (μM)
15b	3	2-pyridinyl	<i>trans</i>	0.53
14b	3	3-pyridinyl	<i>trans</i>	0.75
12b	3	4-pyridinyl	<i>trans</i>	2.1
15b	3	2-pyridinyl	<i>cis</i>	11.5
14b	3	3-pyridinyl	<i>cis</i>	24
12b	3	4-pyridinyl	<i>cis</i>	60
7b	1	3-pyridinyl	<i>trans</i>	100
7a	1	3-pyridinyl	<i>cis</i>	135

61

Table 4


$\text{Ar}-(\text{CH}_2)_n-\underset{\text{H}}{\underset{ }{\text{N}}}-\text{C}_6\text{H}_{10}-\text{C}_6\text{H}_4-\text{OH}$						
Example No.	N	Ar	<i>Cis/Trans</i>	NR1a/NR2B Oocyte IC ₅₀ (μM)	Alpha 1 cocn IC ₅₀ (μM)	D2 Raclopride IC ₅₀ (μM)
28	3	4-methoxy phenyl	<i>Trans</i>	0.07	2.3	2.97
8b	2	4-methoxy phenyl	<i>Trans</i>	0.24	5.10	1.90
5b	2	4-fluoro phenyl	<i>Trans</i>	0.75		
5a	2	4-fluoro phenyl	<i>Cis</i>	1.2	10	2.7
8a	2	4-methoxy phenyl	<i>Cis</i>	2.4	9.20	5.00

While the forms of the invention exemplified herein such as, for example, the named species of Formulas I-IV, and the recitation of treatment of Parkinson's constitute presently preferred embodiments, many others are possible. It is not intended that said recited species of Formulas I-IV and preferred methods of use should, in any manner, limit or restrict the invention from the full scope claimed herein. It is not intended herein to name all of the possible equivalent forms or ramifications of the invention. It is understood that the terms used herein are merely descriptive, rather than limiting. For example, the term "Parkinson's disease" is merely descriptive, and not limiting, of the term "neurodegenerative disease."

CLAIMS





What is claimed is:

1. A compound of Formula I



or a pharmaceutically acceptable salt thereof
wherein:

Ar is substituted 1 to 3 times or unsubstituted aryl or substituted 1-3 times
or unsubstituted heteroaryl, which heteroaryl is from 5 to 14 atoms
having from 1 to 2 heteroatoms selected from N, O, and S wherein
the substituents are selected from the groups F, Cl, Br, I, OH, NH₂,
SH, CN, NO₂, OCH₃, OC(O)CH₃, CF₃, OCH₂CH₂OH,
NHC(O)CH₃, NHCH₃, or N(CH₃)₂;



d is an integer of from 1 to 2;

n is an integer from 1 to 6;

q is an integer from 0 to 6;

R₁ and R₂ are independently selected from the group consisting of

hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, aralkyl, or

N(R₄)(R₅) wherein R₄ and R₅ are independently selected from

hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, aminoalkyl,

hydroxyalkyl and thioalkyl;

R is hydrogen, alkyl, C(O)R₆, C(O)OR₆, C(O)NHR₆, aralkyl,

hydroxyalkyl, aminoalkyl, amino(hydroxy)alkyl, carboxyalkyl, or

OH wherein R₆ is alkyl or aralkyl;

Y is a hydrogen bond donor group;

X is independently selected from hydrogen or an electron withdrawing group; and

* denotes *cis* or *trans* or a mixture thereof.

2. A compound according to Claim 1 wherein:

Y is a hydrogen bond donor group selected from the group consisting of

OH, heterocycle, which heterocycle is a carboxylic acid or an

amide isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl,

C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is

alkyl, aralkyl, or aryl; and

X is independently selected from hydrogen or an electron withdrawing

group selected from the group consisting of halogen, nitro, cyano,

aminoalkyl, CF₃, C(O)CH₃, and haloalkyl.

3. A compound according to Claim 1 wherein:

Ar is unsubstituted or substituted phenyl;

Y is a hydrogen bond donor group selected from the group consisting of

OH, heterocycle, which heterocycle is a carboxylic acid or an

amide isostere, NH₂, SH and NHR₇, wherein R₇ is alkyl, aralkyl,

$C(O)R_8$, $C(O)OR_8$, $C(O)NHR_8$, SO_2R_8 , or SO_2NHR_8 and R_8 is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF_3 , $C(O)CH_3$, and haloalkyl; and

* denotes *trans*.

4. A compound according to Claim 1 wherein:

Ar is unsubstituted or substituted phenyl;

Z is as defined in Claim 1 and further a group whereby Ar and the nitrogen atom in Formula I are separated by from 2 to 4 atoms;

Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH_2 , SH, and NHR_7 , wherein R_7 is alkyl, aralkyl, $C(O)R_8$, $C(O)OR_8$, $C(O)NHR_8$, SO_2R_8 , or SO_2NHR_8 and R_8 is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF_3 , $C(O)CH_3$, and haloalkyl; and

* denotes *trans*.

5. A compound according to Claim 1 wherein:

Ar is unsubstituted or substituted phenyl;

Z is $-CH_2-(CH_2)_m-$, $-(CH_2)_m-\overset{\overset{O}{\parallel}}{C}-$, $-O-(CH_2)_m-$, $-(CH_2)_m-\overset{\overset{CH_3}{|}}{CH}-$,
 $-(CH_2)_m-\overset{\overset{OH}{|}}{CH}-CH_2-$, $-O-\overset{\overset{CH_3}{|}}{C}-\overset{\overset{O}{\parallel}}{C}-$, $-S-(CH_2)_m-$, $-C\equiv C-CH_2$, or
 $-C\equiv C-(CH_2)_2-$

wherein m is an integer 1-3;

R is hydrogen, methyl, or C(O)CH₃;

Y is a hydrogen bond donor group, which group is OH;

X is hydrogen; and

* denotes *trans*.

- 5 6. A compound according to Claim 1 selected from:
- 4-{4-[Ethyl(3-phenylpropyl)amino]cyclohexyl}phenol;
- 4-{4-[Isopropyl(3-phenylpropyl)amino]cyclohexyl}phenol;
- cis*-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol;
- trans*-4-[4-(4-Phenylbutylamino)cyclohexyl]phenol;
- 10 *cis*-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol;
- trans*-4-[4-(3-Phenylpropylamino)cyclohexyl]phenol;
- 4-(4-Phenethylaminocyclohexyl)phenol;
- trans*-4-(4-Benzylaminocyclohexyl)phenol;
- cis*-4-(4-Benzylaminocyclohexyl)phenol;
- 15 *trans*-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol;
- cis*-4-{4-[2-(4-Fluorophenyl)ethylamino]cyclohexyl}phenol;
- trans*-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
- cis*-4-[4-(1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
- trans*-4-[4-((R)-1-Methyl-3-phenylpropylamino)cyclohexyl]-
- 20 phenol;
- trans*-4-[4-((S)-1-Methyl-3-phenylpropylamino)cyclohexyl]phenol;
- trans*-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol;
- cis*-4-{4-[(Pyridin-3-ylmethyl)amino]cyclohexyl}phenol;
- trans*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol;
- 25 *cis*-4-{4-[2-(4-Methoxyphenyl)ethylamino]cyclohexyl}phenol;
- 4-[4-(5-Phenylpentylamino)cyclohexyl]phenol;
- trans*-4-[4-((R)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]
- phenol;
- cis*-4-[4-((R)-1-Hydroxymethyl-2-phenylethylamino)cyclohexyl]
- 30 phenol;
- trans*-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol;
- cis*-4-[4-(2-Phenoxyethylamino)cyclohexyl]phenol;

trans-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol;
cis-4-[4-(3-Pyridin-4-ylpropylamino)cyclohexyl]phenol;
 4-[4-((*S*)-1-Methyl-2-phenylethylamino)cyclohexyl]phenol;
trans-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol;
cis-4-[4-(3-Pyridin-3-ylpropylamino)cyclohexyl]phenol;
trans-4-[4-(3-Pyridin-2-ylpropylamino)cyclohexyl]phenol;
cis-4-[4-(3-Pyridin-2-ylpropylamino)cyclohexyl]phenol;
 N-Benzyl-N-[4-(4-hydroxyphenyl)cyclohexyl]acetamide;
 N-[4-(4-Hydroxyphenyl)cyclohexyl]-N-(3-phenylpropyl)

acetamide;

N-[4-(4-Hydroxyphenyl)cyclohexyl]-N-(3-phenylpropyl)carbamic
 acid methyl ester;


N-Benzyl-N-[4-(4-hydroxyphenyl)cyclohexyl]carbamic acid
 methyl ester;

4-{4-[Methyl-(3-phenylpropyl)amino]cyclohexyl}phenol;
 N-[4-(4-Hydroxyphenyl)cyclohexyl]-3-phenylpropionamide;
 N-[4-(4-Hydroxyphenyl)cyclohexyl]-2-methyl-2-
 phenoxypropionamide;

4-[4-(3-Phenylprop-2-ynylamino)cyclohexyl]phenol;
 4-[4-(2-Phenylsulfanylethylamino)cyclohexyl]phenol;
 4-{4-[3-(4-Methoxyphenyl)propylamino]cyclohexyl}phenol;
 4-{4-[Benzyl(3-phenylpropyl)amino]cyclohexyl}phenol;
 4-{4-[methyl(2-phenoxyethyl)amino]cyclohexyl}phenol; and
 2-Aminomethyl-4-{4-[ethyl(3-phenylpropyl)amino]cyclohexyl}-

phenol.

7. A compound according to Claim 1 of Formula II:




II

or a pharmaceutically acceptable salt thereof

wherein:

Ar is aryl or heteroaryl, which heteroaryl is from 5 to 14 atoms having from 1 to 2 heteroatoms selected from N, O, and S;



wherein U is $-\overset{\overset{O}{||}}{C}-$, $-\text{CH}_2-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$,

A is $-\overset{\overset{O}{||}}{C}-$, $-\text{CH}_2-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$;

t is an integer from 1 to 3;

R₁ and R₂ are independently selected from hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, thioalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, guanidinyl, (aminocarbonyl)alkyl-, carboxyalkyl-, (methylthio)-alkyl-, or N(R₄)(R₅) wherein R₄ and R₅ are independently selected from hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, ureidoalkyl, aminoalkyl, hydroxyalkyl, or thioalkyl, R₃ is hydrogen, alkyl, OH, or aralkyl;

R is hydrogen, alkyl, C(O)R₆, C(O)OR₆, C(O)NHR₆, aralkyl, hydroxyalkyl, aminoalkyl, amino(hydroxy)alkyl, carboxyalkyl, or OH wherein R₆ is alkyl or aralkyl;

Y is a hydrogen bond donor group;

X is independently selected from hydrogen or an electron withdrawing group; and

* denotes *cis* or *trans* or a mixture thereof.

8. A compound according to Claim 7 wherein:

Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH and NHR₇, wherein R₇ is alkyl, aralkyl,

C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl; and

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl.

9. A compound according to Claim 7 wherein:

Ar is unsubstituted or substituted phenyl;

Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

10. A compound according to Claim 7 wherein:

Ar is unsubstituted or substituted phenyl;

Ar and the nitrogen atom bearing R are separated by 3 or 4 atoms;


Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *trans*.

11. A compound according to Claim 7 wherein:

Ar is unsubstituted or substituted phenyl;



R is hydrogen or methyl;


Y is a hydrogen bond donor group, which group is OH;

X is hydrogen; and


* denotes *trans*.

12. The compound according to Claim 7, namely
 4-[4-(2-Phenylaminoethylamino)cyclohexyl]phenol.

13. A compound of Claim 1 of Formula III



14. A compound of Claim 1 of Formula IV



15. A compound according to Claim 1 wherein:

Ar is unsubstituted or substituted phenyl;

Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *cis*.

16. A compound according to Claim 7 wherein:

Ar is unsubstituted or substituted phenyl;

Y is a hydrogen bond donor group selected from the group consisting of OH, heterocycle, which heterocycle is a carboxylic acid or an amide isostere, NH₂, SH, and NHR₇, wherein R₇ is alkyl, aralkyl, C(O)R₈, C(O)OR₈, C(O)NHR₈, SO₂R₈, or SO₂NHR₈ and R₈ is alkyl, aralkyl, or aryl;

X is independently selected from hydrogen or an electron withdrawing group selected from the group consisting of halogen, nitro, cyano, aminoalkyl, CF₃, C(O)CH₃, and haloalkyl; and

* denotes *cis*.

17. A pharmaceutical composition useful for treating disorders responsive to the selective blockade of N-methyl-D-aspartate receptor subtypes, optionally disorders as stroke, cerebral ischemia, trauma, hypoglycemia, neurodegenerative disorders, anxiety, depression, migraine headache, convulsions, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence, the compositions comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of at least one compound of Claim 1 or Claim 7.
18. A pharmaceutical composition according to Claim 17, wherein the neurodegenerative disorder is Parkinson's disease.
19. A pharmaceutical composition according to Claim 17, further comprising a dopamine agonist or precursor thereof in amount effective to treat Parkinson's disease.
20. A method for treating disorders responsive to the selective blockade of N-methyl-D-aspartate receptor subtypes in a mammal suffering thereof which comprises administering in unit dosage form at least one compound represented by Formula I of Claim 1 or Formula II of Claim 7.
21. A method according to claim 20, wherein the disorder is Parkinson's disease.
22. A method according to Claim 20, further comprising administering in unit dosage form a compound any one of Formulas I-IV to a mammal suffering from Parkinson's disease.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 01/13176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C215/54 C07C217/60 C07C215/56 C07C217/16 C07C271/24
 C07C233/23 C07C323/25 C07D213/38 A61K31/137 A61K31/4402
 A61K31/4406 A61K31/4409 A61K31/27 A61K31/165 A61P25/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 982 026 A (HOFFMANN LA ROCHE) 1 March 2000 (2000-03-01) page 3, compounds of lines 48-56 page 2, line 1 -page 3, line 45 examples ----	1-22
A	EP 0 940 387 A (TOKYO TANABE CO) 8 September 1999 (1999-09-08) page 3, line 46 -page 4, line 48 example 1 ----	1-22
A	DE 44 38 020 A (THOMAE GMBH DR K) 2 May 1996 (1996-05-02) page 4, line 35 -page 6, line 6 ----- -/--	1-22



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 August 2001

Date of mailing of the international search report

28/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

O'Sullivan, P

INTERNATIONAL SEARCH REPORT

Int onal Application No

PCT/US 01/13176

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 00197 A (KESTEN SUZANNE ROSS ;WARNER LAMBERT CO (US); WRIGHT JONATHAN L (US) 6 January 2000 (2000-01-06) page 5, line 1 -page 7, line 32 ---	1-22
A	US 5 595 993 A (CATT JOHN D ET AL) 21 January 1997 (1997-01-21) column 2, line 4 - line 32 ---	1-22
A	EP 0 507 291 A (YOSHITOMI PHARMACEUTICAL) 7 October 1992 (1992-10-07) page 3, line 30 -page 4, line 49 ---	1-22
A	CANTARELLI G ET AL: "FENILCICLOESILAMMINE E DERIVATI NOTA III - 3- E 4-FENILCICLOESILAMMINE MONO- E DISOSTITUITE ALL'AZOTO LORO ATTIVITA ANESTETICA LOCALE E PRESSORIA" FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 25, no. 4, 1970, pages 248-294, XP001020310 page 250, compounds IIa - IIa page 255, compounds IVa, IVb, VIa, VIb table I, examples 21-26, 38 table VI, examples 73,74,76 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/13176

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0982026 A	01-03-2000	AU 4453799 A	04-05-2000
		BR 9903779 A	19-09-2000
		CN 1248439 A	29-03-2000
		HR 990256 A	30-04-2000
		HU 9902737 A	28-06-2000
		JP 2000109429 A	18-04-2000
		NO 993948 A	21-02-2000
		PL 334949 A	28-02-2000
		TR 9902015 A	21-03-2000
		US 6184236 B	06-02-2001
EP 0940387 A	08-09-1999	AU 715216 B	20-01-2000
		AU 7335896 A	15-05-1997
		NO 981858 A	24-06-1998
		US 6069176 A	30-05-2000
		CA 2235840 A	01-05-1997
		CZ 9801265 A	16-09-1998
		HU 9802318 A	30-08-1999
		WO 9715549 A	01-05-1997
DE 4438020 A	02-05-1996	NONE	
WO 0000197 A	06-01-2000	AU 4830399 A	17-01-2000
		BR 9911575 A	20-03-2001
		CN 1304307 T	18-07-2001
		EP 1089735 A	11-04-2001
		NO 20006482 A	19-12-2000
US 5595993 A	21-01-1997	US 5352678 A	04-10-1994
		AT 123774 T	15-06-1995
		CA 2091204 A,C	12-09-1993
		DE 69300192 D	20-07-1995
		DK 560669 T	02-10-1995
		EP 0560669 A	15-09-1993
		ES 2076051 T	16-10-1995
		GR 3017368 T	31-12-1995
		HK 1005030 A	18-12-1998
		JP 2101094 C	22-10-1996
		JP 6080655 A	22-03-1994
		JP 7110857 B	29-11-1995
		US 6153611 A	28-11-2000
EP 0507291 A	07-10-1992	CA 2065086 A	05-10-1992
		HU 61724 A	01-03-1993
		JP 5208948 A	20-08-1993
		KR 9411151 B	24-11-1994
		US 5420164 A	30-05-1995